data_2m2r_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2m2r _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.452 -0.357 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.411 ' HA ' HD13 ' A' ' 9' ' ' LEU . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.616 HD23 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.665 HD11 ' N ' ' A' ' 12' ' ' LEU . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.425 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.425 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.481 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.481 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.461 HD13 HG23 ' A' ' 27' ' ' ILE . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.616 ' HB ' HD23 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.417 HG21 ' N ' ' A' ' 32' ' ' CYS . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.417 ' N ' HG21 ' A' ' 31' ' ' VAL . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.425 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m . . . . . 0 CA--C 1.528 0.103 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.426 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.42 HD22 ' N ' ' A' ' 10' ' ' LEU . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.425 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.489 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.548 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.775 0.321 . . . . 0.0 110.407 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.638 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.45 ' HA ' HD11 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.45 HD11 ' HA ' ' A' ' 7' ' ' CYS . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.444 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.502 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.548 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.661 ' HB3' HG21 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.638 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.661 HG21 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.435 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HB3' HD21 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HA ' HD11 ' A' ' 9' ' ' LEU . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.484 HD23 ' HB ' ' A' ' 28' ' ' VAL . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.465 HD22 ' HA ' ' A' ' 12' ' ' LEU . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.461 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.461 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.438 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB3' HD11 ' A' ' 27' ' ' ILE . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 23' ' ' ASP . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.484 ' HB ' HD23 ' A' ' 10' ' ' LEU . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.478 ' HB2' ' HB3' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.152 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.559 ' CB ' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.517 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.526 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.432 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.543 ' HB3' ' HA ' ' A' ' 3' ' ' ALA . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.466 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.511 ' HB3' HG23 ' A' ' 33' ' ' VAL . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.78 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.549 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.549 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.469 HD11 HG22 ' A' ' 27' ' ' ILE . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 29' ' ' ALA . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.517 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.78 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.511 HG23 ' HB3' ' A' ' 18' ' ' CYS . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.545 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.436 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.436 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.545 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.542 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.542 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.462 0.128 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.593 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.44 ' HB3' ' HZ1' ' A' ' 5' ' ' LYS . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.527 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.426 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.455 ' HB2' HD21 ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.568 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.455 HD21 ' HB2' ' A' ' 8' ' ' ASN . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 16' ' ' ALA . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . 0.408 ' H ' ' CG ' ' A' ' 15' ' ' ASP . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.568 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.406 HG21 ' N ' ' A' ' 29' ' ' ALA . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.406 ' N ' HG21 ' A' ' 28' ' ' VAL . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.527 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.593 ' SG ' ' HB3' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.476 ' CB ' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.445 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.659 ' N ' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.423 HG21 HD12 ' A' ' 27' ' ' ILE . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.476 ' HB2' ' CB ' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m . . . . . 0 CA--C 1.523 -0.092 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.448 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.457 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.639 HD22 ' HB3' ' A' ' 22' ' ' PRO . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.457 ' H ' ' C ' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.446 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.466 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.529 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.536 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.639 ' HB3' HD22 ' A' ' 9' ' ' LEU . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.439 ' O ' ' HG ' ' A' ' 9' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.529 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.416 HG12 ' HB2' ' A' ' 21' ' ' ARG . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m . . . . . 0 N--CA 1.453 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.479 ' HA ' HD23 ' A' ' 12' ' ' LEU . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.479 ' N ' HD12 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.52 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.496 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.515 ' O ' ' HB1' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.462 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m . . . . . 0 CA--C 1.518 -0.25 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.822 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.653 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.5 OUTLIER -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.462 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.442 ' HB3' HD13 ' A' ' 27' ' ' ILE . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.442 HD13 ' HB3' ' A' ' 23' ' ' ASP . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.653 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.456 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.597 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m . . . . . 0 N--CA 1.455 -0.18 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.448 ' CB ' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.48 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.472 ' HA ' HD12 ' A' ' 12' ' ' LEU . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.478 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.448 ' HB3' ' CB ' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.46 0.033 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.411 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.456 HD13 ' O ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.724 ' HA ' HG22 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . 0.802 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . 0.48 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.446 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' A' ' 8' ' ' ASN . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.622 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.802 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.518 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.518 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.674 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.617 ' H ' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.443 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . 0.538 ' HA ' HG21 ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.436 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . 0.674 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.538 HG21 ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.467 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.442 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.53 HD21 ' HA ' ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.465 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.523 ' HB3' HD13 ' A' ' 27' ' ' ILE . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . 0.523 HD13 ' HB3' ' A' ' 23' ' ' ASP . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . 0.53 ' HA ' HD21 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.404 HG23 ' N ' ' A' ' 32' ' ' CYS . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m . . . . . 0 N--CA 1.453 -0.316 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HA ' HD11 ' A' ' 9' ' ' LEU . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.755 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . 0.424 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . 0.512 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . 0.512 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m . . . . . 0 N--CA 1.454 -0.233 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' CYS . . . . . 0.613 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 9' ' ' LEU . 0.7 OUTLIER -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' LEU . . . . . 0.41 HD21 ' HB3' ' A' ' 20' ' ' CYS . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LEU . . . . . 0.408 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' THR . . . . . 0.613 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' CYS . . . . . 0.41 ' HB3' HD21 ' A' ' 9' ' ' LEU . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.553 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.835 0 N-CA-C 111.401 -0.679 . . . . 0.0 111.401 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m -113.48 35.37 4.04 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 -179.0 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.411 ' HA ' HD13 ' A' ' 9' ' ' LEU . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.616 HD23 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.665 HD11 ' N ' ' A' ' 12' ' ' LEU . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.425 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.425 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.481 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.481 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.461 HD13 HG23 ' A' ' 27' ' ' ILE . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.616 ' HB ' HD23 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.417 HG21 ' N ' ' A' ' 32' ' ' CYS . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.417 ' N ' HG21 ' A' ' 31' ' ' VAL . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.461 ' H2 ' ' C ' ' A' ' 33' ' ' VAL . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 112.142 -0.383 . . . . 0.0 112.142 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.425 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m -74.56 -33.25 62.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.426 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.42 HD22 ' N ' ' A' ' 10' ' ' LEU . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.425 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.489 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.489 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.528 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.461 ' C ' ' H2 ' ' A' ' 1' ' ' GLY . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.853 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.548 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p -63.65 -43.48 96.64 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.08 0.44 . . . . 0.0 110.407 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.638 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.45 ' HA ' HD11 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.45 HD11 ' HA ' ' A' ' 7' ' ' CYS . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.444 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.502 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.548 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.661 ' HB3' HG21 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.638 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.661 HG21 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.402 ' H1 ' ' C ' ' A' ' 33' ' ' VAL . . . . . . . . 0 N--CA 1.483 1.794 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.65 -28.41 51.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.478 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.435 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.443 ' HB3' HD21 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.506 ' HA ' HD11 ' A' ' 9' ' ' LEU . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.484 HD23 ' HB ' ' A' ' 28' ' ' VAL . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.465 HD22 ' HA ' ' A' ' 12' ' ' LEU . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.461 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.461 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.438 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.438 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.405 ' HB3' HD11 ' A' ' 27' ' ' ILE . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.405 HD11 ' HB3' ' A' ' 23' ' ' ASP . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.484 ' HB ' HD23 ' A' ' 10' ' ' LEU . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.478 ' HB2' ' HB3' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.402 ' C ' ' H1 ' ' A' ' 1' ' ' GLY . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.813 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m -85.54 -18.08 34.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.559 ' CB ' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.517 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.409 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.526 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.432 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.543 ' HB3' ' HA ' ' A' ' 3' ' ' ALA . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.466 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.511 ' HB3' HG23 ' A' ' 33' ' ' VAL . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.78 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.549 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.549 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.469 HD11 HG22 ' A' ' 27' ' ' ILE . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.41 HG23 ' N ' ' A' ' 29' ' ' ALA . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.517 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.78 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.511 HG23 ' HB3' ' A' ' 18' ' ' CYS . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 111.585 -0.606 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.545 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m -121.66 38.94 3.98 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.436 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.483 HD13 ' O ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.436 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.545 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.542 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.542 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.459 -0.657 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.55 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p -167.01 -29.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.593 ' HB3' ' SG ' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.44 ' HB3' ' HZ1' ' A' ' 5' ' ' LYS . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.527 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.426 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.455 ' HB2' HD21 ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.568 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.455 HD21 ' HB2' ' A' ' 8' ' ' ASN . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.448 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.55 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.408 ' CG ' ' H ' ' A' ' 16' ' ' ALA . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . 0.408 ' H ' ' CG ' ' A' ' 15' ' ' ASP . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.568 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.406 HG21 ' N ' ' A' ' 29' ' ' ALA . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.406 ' N ' HG21 ' A' ' 28' ' ' VAL . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.527 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.593 ' SG ' ' HB3' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.486 ' H3 ' ' C ' ' A' ' 33' ' ' VAL . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 112.344 -0.302 . . . . 0.0 112.344 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -93.55 30.53 1.73 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.476 ' CB ' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.445 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.659 ' N ' HD12 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.423 HG21 HD12 ' A' ' 27' ' ' ILE . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.476 ' HB2' ' CB ' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.486 ' C ' ' H3 ' ' A' ' 1' ' ' GLY . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.483 ' H1 ' ' C ' ' A' ' 33' ' ' VAL . . . . . . . . 0 N--CA 1.483 1.821 0 N-CA-C 111.491 -0.643 . . . . 0.0 111.491 . . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.466 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m -90.5 23.07 3.14 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.448 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.457 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.639 HD22 ' HB3' ' A' ' 22' ' ' PRO . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.457 ' H ' ' C ' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.446 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.466 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.529 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.536 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.639 ' HB3' HD22 ' A' ' 9' ' ' LEU . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.439 ' O ' ' HG ' ' A' ' 9' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.529 ' HA ' ' HA ' ' A' ' 20' ' ' CYS . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.483 ' C ' ' H1 ' ' A' ' 1' ' ' GLY . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.52 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m -120.92 33.81 5.43 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.479 ' HA ' HD23 ' A' ' 12' ' ' LEU . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.479 ' N ' HD12 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.417 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.52 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.496 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m -92.52 -3.36 55.23 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 -178.971 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.515 ' HB1' ' O ' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.496 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.515 ' O ' ' HB1' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.59 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.462 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m -113.71 34.49 4.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 -179.738 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.456 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.47 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.822 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.653 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.5 OUTLIER -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.462 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.442 ' HB3' HD13 ' A' ' 27' ' ' ILE . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.442 HD13 ' HB3' ' A' ' 23' ' ' ASP . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.653 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.456 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.597 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m -91.13 -17.64 25.8 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 -179.39 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.448 ' CB ' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.48 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.472 ' HA ' HD12 ' A' ' 12' ' ' LEU . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . 0.597 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.43 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.478 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.478 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.48 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.448 ' HB3' ' CB ' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . 0.546 ' H2 ' ' C ' ' A' ' 33' ' ' VAL . . . . . . . . 0 N--CA 1.483 1.816 0 N-CA-C 111.796 -0.522 . . . . 0.0 111.796 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.23 -25.34 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.48 ' HB3' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.411 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.456 HD13 ' O ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.724 ' HA ' HG22 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.48 ' HB2' ' HB3' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.724 HG22 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.82 24.99 9.81 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 -179.034 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . 0.802 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . 0.48 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.446 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . 0.408 ' H ' ' C ' ' A' ' 8' ' ' ASN . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.622 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.446 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.802 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.518 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m -114.9 33.66 5.27 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 -179.528 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.518 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.737 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.443 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m -126.61 39.18 3.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 -179.452 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.674 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.617 ' H ' HD11 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.443 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . 0.538 ' HA ' HG21 ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.436 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.436 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . 0.674 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.538 HG21 ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.467 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m -123.77 40.43 3.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 -179.532 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.442 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.53 HD21 ' HA ' ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.465 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.523 ' HB3' HD13 ' A' ' 27' ' ' ILE . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . 0.523 HD13 ' HB3' ' A' ' 23' ' ' ASP . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.53 ' HA ' HD21 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.404 HG23 ' N ' ' A' ' 32' ' ' CYS . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.442 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . 0.424 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m -118.23 36.12 4.48 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.472 ' HA ' HD11 ' A' ' 9' ' ' LEU . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.755 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . 0.424 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . 0.512 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . 0.512 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m -119.71 34.51 5.19 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' CYS . . . . . 0.613 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . 0.406 ' O ' ' HB2' ' A' ' 9' ' ' LEU . 0.7 OUTLIER -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' LEU . . . . . 0.41 HD21 ' HB3' ' A' ' 20' ' ' CYS . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LEU . . . . . 0.408 HD21 ' HA ' ' A' ' 12' ' ' LEU . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' THR . . . . . 0.613 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' CYS . . . . . 0.41 ' HB3' HD21 ' A' ' 9' ' ' LEU . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.553 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' CYS . . . . . 0.506 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.452 -0.357 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.487 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.577 ' HB ' HD21 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.443 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m . . . . . 0 CA--C 1.528 0.103 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.66 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.583 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.443 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.501 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.501 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.66 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.561 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.775 0.321 . . . . 0.0 110.407 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.645 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.439 ' HA ' HD12 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.611 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.611 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.443 HD13 ' N ' ' A' ' 13' ' ' THR . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.443 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.482 ' HB3' HG23 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.645 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.763 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.708 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.425 HD13 ' N ' ' A' ' 13' ' ' THR . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' HD13 ' A' ' 12' ' ' LEU . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.467 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.45 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.45 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.763 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.152 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.864 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.596 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.405 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.596 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.764 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.565 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.864 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.553 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.401 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HG ' ' H ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.553 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.554 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.554 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 21' ' ' ARG . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.57 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.462 0.128 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.559 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.453 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.417 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.584 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.429 HD12 ' N ' ' A' ' 11' ' ' GLY . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' N ' HD12 ' A' ' 10' ' ' LEU . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.438 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.57 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.584 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLY . . . . . 0.52 ' O ' ' HB1' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.559 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.614 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.923 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.923 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.485 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m . . . . . 0 CA--C 1.523 -0.092 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.654 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.477 ' SG ' HG22 ' A' ' 13' ' ' THR . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.567 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.483 HD12 HD22 ' A' ' 10' ' ' LEU . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.516 HD13 ' H ' ' A' ' 14' ' ' CYS . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.477 HG22 ' SG ' ' A' ' 7' ' ' CYS . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.541 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.541 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.466 ' HB ' HD21 ' A' ' 10' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.654 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 21' ' ' ARG . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m . . . . . 0 N--CA 1.453 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 13' ' ' THR . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.532 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.502 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.502 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m . . . . . 0 CA--C 1.518 -0.25 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.513 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.814 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.675 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 37.3 t-20 -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.422 ' HB3' ' HB3' ' A' ' 2' ' ' CYS . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.675 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.619 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m . . . . . 0 N--CA 1.455 -0.18 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.827 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.498 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.496 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.827 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.46 0.033 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.732 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.671 ' HA ' HG23 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.732 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.671 HG23 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 3' ' ' ALA . . . . . 0.809 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' GLY . . . . . 0.4 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 20' ' ' CYS . . . . . 0.625 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.809 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.417 HD22 ' HA ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.523 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.696 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.707 ' H ' HD13 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.452 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' CYS . . . . . 0.425 ' HA ' ' CG2' ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.432 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ALA . . . . . 0.696 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.417 HG13 HH21 ' A' ' 21' ' ' ARG . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.457 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.407 HD11 HG12 ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.451 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' VAL . . . . . 0.407 HG12 HD11 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.457 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m . . . . . 0 N--CA 1.453 -0.316 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.7 t-20 -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.781 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ASP . . . . . 0.433 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PRO . . . . . 0.521 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m . . . . . 0 N--CA 1.454 -0.233 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 7' ' ' CYS . . . . . 0.619 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 9' ' ' LEU . 40.1 t-20 -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 9' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 8' ' ' ASN . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 7' ' ' CYS . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' THR . . . . . 0.619 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.577 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.835 0 N-CA-C 111.401 -0.679 . . . . 0.0 111.401 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m -113.48 35.37 4.04 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 -179.0 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.487 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.577 ' HB ' HD21 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 112.142 -0.383 . . . . 0.0 112.142 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.443 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m -74.56 -33.25 62.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.66 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.583 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.443 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.501 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.501 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.66 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.853 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.561 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p -63.65 -43.48 96.64 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.08 0.44 . . . . 0.0 110.407 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.645 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.439 ' HA ' HD12 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.611 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.611 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.443 HD13 ' N ' ' A' ' 13' ' ' THR . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.443 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.482 ' HB3' HG23 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.645 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.794 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.65 -28.41 51.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.763 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.708 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.425 HD13 ' N ' ' A' ' 13' ' ' THR . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' HD13 ' A' ' 12' ' ' LEU . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.467 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.45 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.45 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.763 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.813 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m -85.54 -18.08 34.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.864 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.596 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.405 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.596 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.764 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.565 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.864 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 111.585 -0.606 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.553 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m -121.66 38.94 3.98 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.401 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HG ' ' H ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.553 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.554 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.554 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 21' ' ' ARG . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.459 -0.657 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.57 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p -167.01 -29.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.559 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.453 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.417 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.584 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.429 HD12 ' N ' ' A' ' 11' ' ' GLY . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' N ' HD12 ' A' ' 10' ' ' LEU . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.438 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.57 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.584 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLY . . . . . 0.52 ' O ' ' HB1' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.559 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.614 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 112.344 -0.302 . . . . 0.0 112.344 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -93.55 30.53 1.73 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.923 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.923 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.821 0 N-CA-C 111.491 -0.643 . . . . 0.0 111.491 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.485 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m -90.5 23.07 3.14 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.654 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.477 ' SG ' HG22 ' A' ' 13' ' ' THR . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.483 HD12 HD22 ' A' ' 10' ' ' LEU . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.516 HD13 ' H ' ' A' ' 14' ' ' CYS . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.477 HG22 ' SG ' ' A' ' 7' ' ' CYS . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.541 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.541 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.466 ' HB ' HD21 ' A' ' 10' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.654 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 21' ' ' ARG . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m -120.92 33.81 5.43 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 13' ' ' THR . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.532 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.502 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m -92.52 -3.36 55.23 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 -178.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.502 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.59 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m -113.71 34.49 4.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 -179.738 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.513 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.814 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.675 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 37.3 t-20 -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.422 ' HB3' ' HB3' ' A' ' 2' ' ' CYS . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.675 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.619 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m -91.13 -17.64 25.8 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 -179.39 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.827 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.498 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.496 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.827 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.816 0 N-CA-C 111.796 -0.522 . . . . 0.0 111.796 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.23 -25.34 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.732 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.671 ' HA ' HG23 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.732 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.671 HG23 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.82 24.99 9.81 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 -179.034 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.809 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.4 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 20' ' ' CYS . . . . . 0.625 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.809 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m -114.9 33.66 5.27 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 -179.528 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.417 HD22 ' HA ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.523 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.737 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m -126.61 39.18 3.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 -179.452 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.696 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.707 ' H ' HD13 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.452 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' CYS . . . . . 0.425 ' HA ' ' CG2' ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.432 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ALA . . . . . 0.696 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.417 HG13 HH21 ' A' ' 21' ' ' ARG . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m -123.77 40.43 3.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 -179.532 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.457 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.407 HD11 HG12 ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.451 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.407 HG12 HD11 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.457 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m -118.23 36.12 4.48 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 34.7 t-20 -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.781 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ASP . . . . . 0.433 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PRO . . . . . 0.521 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m -119.71 34.51 5.19 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 7' ' ' CYS . . . . . 0.619 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ASN . . . . . 0.405 ' O ' ' HB2' ' A' ' 9' ' ' LEU . 40.1 t-20 -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 8' ' ' ASN . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 7' ' ' CYS . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' THR . . . . . 0.619 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.577 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m . . . . . 0 N--CA 1.452 -0.357 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.487 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.577 ' HB ' HD21 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.443 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m . . . . . 0 CA--C 1.528 0.103 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.66 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.583 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.443 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.501 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.501 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.66 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.561 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p . . . . . 0 N--CA 1.454 -0.25 0 CA-C-O 120.775 0.321 . . . . 0.0 110.407 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.645 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.439 ' HA ' HD12 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.611 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.611 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.443 HD13 ' N ' ' A' ' 13' ' ' THR . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.443 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.482 ' HB3' HG23 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.645 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m . . . . . 0 N--CA 1.457 -0.089 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.763 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.708 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.425 HD13 ' N ' ' A' ' 13' ' ' THR . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' HD13 ' A' ' 12' ' ' LEU . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.467 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.467 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.45 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.45 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.763 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m . . . . . 0 N--CA 1.456 -0.152 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.864 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.596 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.405 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.596 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.764 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.565 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.864 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.553 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m . . . . . 0 N--CA 1.453 -0.28 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.401 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HG ' ' H ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.553 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.554 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.554 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 21' ' ' ARG . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.57 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p . . . . . 0 N--CA 1.462 0.128 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.559 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.453 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.417 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.584 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.429 HD12 ' N ' ' A' ' 11' ' ' GLY . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.429 ' N ' HD12 ' A' ' 10' ' ' LEU . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.438 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.57 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.584 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . 0.52 ' O ' ' HB1' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.559 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.614 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m . . . . . 0 CA--C 1.518 -0.262 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.923 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.923 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.485 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m . . . . . 0 CA--C 1.523 -0.092 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.654 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.477 ' SG ' HG22 ' A' ' 13' ' ' THR . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.567 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.483 HD12 HD22 ' A' ' 10' ' ' LEU . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.516 HD13 ' H ' ' A' ' 14' ' ' CYS . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.477 HG22 ' SG ' ' A' ' 7' ' ' CYS . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.516 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.541 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.541 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.466 ' HB ' HD21 ' A' ' 10' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.654 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 21' ' ' ARG . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m . . . . . 0 N--CA 1.453 -0.302 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 13' ' ' THR . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.532 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.502 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m . . . . . 0 N--CA 1.455 -0.178 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.502 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m . . . . . 0 CA--C 1.518 -0.25 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.513 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.814 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.675 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.5 OUTLIER -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.422 ' HB3' ' HB3' ' A' ' 2' ' ' CYS . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.434 HG23 HD21 ' A' ' 8' ' ' ASN . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.675 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.619 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m . . . . . 0 N--CA 1.455 -0.18 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.827 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.498 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.496 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.827 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m . . . . . 0 N--CA 1.46 0.033 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.732 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.671 ' HA ' HG23 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.732 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.671 HG23 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . 0.809 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . 0.4 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . 0.625 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.809 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m . . . . . 0 N--CA 1.45 -0.457 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.417 HD22 ' HA ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.523 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m . . . . . 0 N--CA 1.454 -0.256 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.696 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.707 ' H ' HD13 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.452 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . 0.425 ' HA ' ' CG2' ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.432 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . 0.696 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.417 HG13 HH21 ' A' ' 21' ' ' ARG . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m . . . . . 0 N--CA 1.453 -0.285 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.457 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.407 HD11 HG12 ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.451 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.407 HG12 HD11 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.457 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m . . . . . 0 N--CA 1.453 -0.316 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.781 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . 0.433 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . 0.521 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m . . . . . 0 N--CA 1.454 -0.233 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' CYS . . . . . 0.619 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ASN . . . . . 0.426 HD21 HG23 ' A' ' 28' ' ' VAL . 0.7 OUTLIER -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 8' ' ' ASN . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 7' ' ' CYS . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . 0.619 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' VAL . . . . . 0.426 HG23 HD21 ' A' ' 8' ' ' ASN . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.577 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.835 0 N-CA-C 111.401 -0.679 . . . . 0.0 111.401 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 2.4 m -113.48 35.37 4.04 Favored 'General case' 0 C--N 1.323 -0.57 0 CA-C-O 122.027 0.918 . . . . 0.0 109.802 -179.0 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.64 87.62 3.31 Favored 'General case' 0 C--N 1.319 -0.746 0 CA-C-N 114.692 -1.14 . . . . 0.0 111.28 -179.727 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.11 -42.35 99.72 Favored Glycine 0 N--CA 1.451 -0.303 0 CA-C-N 115.737 -0.665 . . . . 0.0 111.954 -179.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 52.0 tptt -174.22 -50.76 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.305 0 CA-C-O 120.817 0.341 . . . . 0.0 110.19 179.163 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.93 158.57 7.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.57 -179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.5 t -150.81 127.32 10.78 Favored 'General case' 0 C--N 1.323 -0.576 0 CA-C-O 120.851 0.358 . . . . 0.0 110.78 179.711 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.568 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.2 m120 -94.04 136.0 34.8 Favored 'General case' 0 C--N 1.321 -0.655 0 N-CA-C 109.629 -0.508 . . . . 0.0 109.629 178.862 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 22.1 tp -74.33 47.14 0.28 Allowed 'General case' 0 CA--C 1.536 0.404 0 CA-C-O 121.373 0.606 . . . . 0.0 110.991 -179.67 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.577 HD21 ' HB ' ' A' ' 28' ' ' VAL . 3.2 mm? -126.14 25.42 6.71 Favored 'General case' 0 C--N 1.325 -0.5 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.335 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 162.37 -131.39 2.51 Favored Glycine 0 N--CA 1.445 -0.7 0 CA-C-N 115.263 -0.88 . . . . 0.0 111.166 -179.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -158.44 142.34 15.49 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-O 120.839 0.352 . . . . 0.0 110.516 179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -166.93 44.14 0.05 Allowed 'General case' 0 C--N 1.324 -0.536 0 CA-C-O 122.028 0.918 . . . . 0.0 109.275 -179.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 18.3 m -133.51 154.89 50.46 Favored 'General case' 0 C--N 1.326 -0.435 0 CA-C-N 114.96 -1.018 . . . . 0.0 109.838 -179.866 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.434 ' HB2' ' SG ' ' A' ' 18' ' ' CYS . 1.7 m-20 -56.62 150.2 16.11 Favored 'General case' 0 C--N 1.326 -0.422 0 O-C-N 123.689 0.618 . . . . 0.0 110.564 179.934 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -55.51 124.0 15.83 Favored 'General case' 0 C--N 1.327 -0.373 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.206 -179.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 106.78 -34.64 5.57 Favored Glycine 0 N--CA 1.448 -0.553 0 C-N-CA 120.913 -0.66 . . . . 0.0 111.722 -179.307 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.434 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 0.3 OUTLIER -88.46 103.31 15.75 Favored 'General case' 0 C--N 1.323 -0.574 0 CA-C-O 121.192 0.52 . . . . 0.0 109.801 179.854 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.5 p90 -73.66 146.1 44.8 Favored 'General case' 0 C--N 1.324 -0.512 0 CA-C-N 116.105 -0.498 . . . . 0.0 111.238 -179.313 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 43.9 t -73.6 118.21 16.28 Favored 'General case' 0 C--N 1.322 -0.599 0 N-CA-C 108.993 -0.743 . . . . 0.0 108.993 179.261 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.487 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.9 ttp180 -108.16 130.91 22.16 Favored Pre-proline 0 C--N 1.324 -0.542 0 C-N-CA 120.918 -0.313 . . . . 0.0 111.321 -178.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.487 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 43.3 Cg_endo -71.45 161.82 44.29 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.347 2.031 . . . . 0.0 110.474 178.164 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.9 t0 -58.71 -54.76 43.44 Favored 'General case' 0 C--N 1.322 -0.589 0 CA-C-O 120.826 0.346 . . . . 0.0 110.508 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.21 -143.56 3.7 Favored Glycine 0 N--CA 1.442 -0.916 0 C-N-CA 120.45 -0.881 . . . . 0.0 112.282 179.11 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.03 131.26 34.33 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.685 0 CA-C-O 121.101 0.477 . . . . 0.0 111.491 -179.819 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.29 29.03 73.83 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.424 -0.807 . . . . 0.0 113.157 179.681 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -127.02 132.82 69.53 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.441 0 N-CA-C 109.853 -0.425 . . . . 0.0 109.853 179.381 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.577 ' HB ' HD21 ' A' ' 10' ' ' LEU . 24.4 m -89.34 -31.59 5.44 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.756 0 CA-C-N 115.696 -0.684 . . . . 0.0 111.308 -179.451 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.79 147.38 31.85 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.289 179.741 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -167.44 -148.7 5.74 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.025 -179.929 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 10.8 p -153.09 149.46 13.33 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 120.622 0.249 . . . . 0.0 110.801 179.79 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 36.4 m -64.9 137.66 57.89 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.408 -0.36 . . . . 0.0 110.071 179.423 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.7 m . . . . . 0 C--O 1.246 0.878 0 CA-C-O 118.334 -0.841 . . . . 0.0 111.564 -179.765 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.709 0 N-CA-C 112.142 -0.383 . . . . 0.0 112.142 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.443 ' HB3' ' OD2' ' A' ' 15' ' ' ASP . 7.9 m -74.56 -33.25 62.65 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-O 121.159 0.504 . . . . 0.0 110.518 -179.789 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.66 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -60.7 133.25 55.91 Favored 'General case' 0 C--N 1.331 -0.221 0 CA-C-N 115.935 -0.575 . . . . 0.0 111.646 179.851 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.93 -34.35 88.55 Favored Glycine 0 N--CA 1.447 -0.567 0 CA-C-N 115.722 -0.672 . . . . 0.0 112.315 179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.409 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 5.4 ttmm -173.0 -44.94 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.158 0 CA-C-O 120.484 0.183 . . . . 0.0 111.357 179.502 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.77 158.3 42.08 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.672 -0.24 . . . . 0.0 110.501 -179.594 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 8.5 t -151.0 136.12 17.54 Favored 'General case' 0 C--N 1.325 -0.493 0 CA-C-N 116.235 -0.438 . . . . 0.0 110.952 -179.714 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.583 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.1 m120 -101.79 137.6 39.88 Favored 'General case' 0 C--N 1.318 -0.784 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 178.4 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 21.7 tp -72.51 49.37 0.21 Allowed 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.492 0.663 . . . . 0.0 111.396 -179.311 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.583 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.3 mm? -125.86 31.95 5.37 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.776 -0.824 . . . . 0.0 108.776 179.235 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.36 -138.35 5.12 Favored Glycine 0 N--CA 1.444 -0.777 0 CA-C-N 115.222 -0.899 . . . . 0.0 111.357 -179.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -158.61 59.53 0.44 Allowed 'General case' 0 C--N 1.327 -0.409 0 CA-C-O 121.267 0.556 . . . . 0.0 109.694 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.8 t -83.73 50.77 1.87 Allowed 'General case' 0 C--N 1.325 -0.486 0 CA-C-O 121.651 0.738 . . . . 0.0 110.534 179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.449 ' SG ' ' HB2' ' A' ' 20' ' ' CYS . 3.9 m -141.54 152.24 43.94 Favored 'General case' 0 C--N 1.325 -0.482 0 CA-C-N 115.872 -0.603 . . . . 0.0 110.171 -179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.443 ' OD2' ' HB3' ' A' ' 2' ' ' CYS . 40.2 m-20 -60.18 149.14 33.83 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.536 179.484 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.94 124.73 17.64 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.008 -179.588 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.81 -35.79 4.79 Favored Glycine 0 N--CA 1.448 -0.514 0 C-N-CA 120.871 -0.68 . . . . 0.0 111.727 -179.134 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.6 m -88.01 85.89 7.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.037 0.446 . . . . 0.0 109.883 179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.0 p90 -63.15 143.45 57.78 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.75 -179.085 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.545 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 49.4 t -75.54 103.81 5.82 Favored 'General case' 0 C--N 1.326 -0.439 0 CA-C-N 115.563 -0.744 . . . . 0.0 109.085 179.288 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.501 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 13.5 ttp180 -87.2 131.39 44.6 Favored Pre-proline 0 C--N 1.323 -0.547 0 CA-C-N 116.356 -0.384 . . . . 0.0 110.757 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.501 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 37.5 Cg_endo -70.01 159.31 53.68 Favored 'Trans proline' 0 N--CA 1.458 -0.584 0 C-N-CA 122.212 1.941 . . . . 0.0 110.869 178.541 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.2 t70 -58.11 -52.08 67.04 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 120.807 0.337 . . . . 0.0 110.833 -179.215 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.06 -142.9 3.52 Favored Glycine 0 N--CA 1.441 -1.016 0 C-N-CA 120.645 -0.788 . . . . 0.0 112.204 179.263 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -84.52 130.1 36.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.639 0 CA-C-O 121.051 0.453 . . . . 0.0 111.46 -179.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.92 32.7 83.49 Favored Glycine 0 N--CA 1.451 -0.332 0 CA-C-N 115.532 -0.758 . . . . 0.0 113.202 179.64 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.1 mt -126.78 135.23 64.29 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 179.402 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.4 m -89.05 -31.75 5.55 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-N 115.881 -0.6 . . . . 0.0 111.332 -179.372 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -79.74 143.29 34.64 Favored 'General case' 0 C--N 1.325 -0.492 0 CA-C-N 116.362 -0.381 . . . . 0.0 110.089 179.645 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -168.46 -144.98 4.39 Favored Glycine 0 N--CA 1.448 -0.531 0 C-N-CA 120.692 -0.766 . . . . 0.0 112.45 -179.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.5 p -153.43 137.29 8.61 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.567 0 CA-C-O 120.579 0.228 . . . . 0.0 110.749 -179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.66 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 3.0 m -67.03 142.85 57.05 Favored 'General case' 0 C--O 1.237 0.426 0 N-CA-C 109.036 -0.728 . . . . 0.0 109.036 178.926 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 17.0 m . . . . . 0 C--O 1.251 1.134 0 CA-C-O 118.853 -0.594 . . . . 0.0 110.997 179.666 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.853 0 N-CA-C 110.444 -1.062 . . . . 0.0 110.444 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.561 ' CB ' ' HB2' ' A' ' 15' ' ' ASP . 1.3 p -63.65 -43.48 96.64 Favored 'General case' 0 C--N 1.327 -0.395 0 CA-C-N 117.08 0.44 . . . . 0.0 110.407 179.088 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.645 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -66.9 114.52 5.79 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 109.731 -0.47 . . . . 0.0 109.731 178.558 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -82.97 -51.63 4.14 Favored Glycine 0 N--CA 1.449 -0.491 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.43 -179.349 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 38.8 ttmt 179.22 -41.68 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.222 0 CA-C-O 121.151 0.501 . . . . 0.0 109.978 179.842 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -157.96 161.32 38.17 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.555 -0.748 . . . . 0.0 109.657 -179.761 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.439 ' HA ' HD12 ' A' ' 12' ' ' LEU . 53.2 t -151.13 139.05 19.93 Favored 'General case' 0 C--N 1.322 -0.612 0 N-CA-C 110.186 -0.302 . . . . 0.0 110.186 -179.578 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.611 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.5 m120 -124.86 131.09 53.48 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.612 0.244 . . . . 0.0 110.584 -179.98 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.4 tp -74.6 51.72 0.48 Allowed 'General case' 0 CA--C 1.535 0.385 0 CA-C-O 121.34 0.59 . . . . 0.0 110.999 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.611 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -124.65 -44.43 1.97 Allowed 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.819 -0.628 . . . . 0.0 109.727 179.756 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.55 48.58 0.08 OUTLIER Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.417 -0.81 . . . . 0.0 111.158 -179.792 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.443 HD13 ' N ' ' A' ' 13' ' ' THR . 2.8 tm? -148.69 138.78 22.32 Favored 'General case' 0 C--N 1.325 -0.474 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -179.286 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.443 ' N ' HD13 ' A' ' 12' ' ' LEU . 9.1 t -150.14 142.3 24.09 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.719 -0.474 . . . . 0.0 109.719 179.965 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' CYS . 36.7 m -91.15 -157.12 0.48 Allowed 'General case' 0 C--N 1.322 -0.606 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.144 -179.589 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.561 ' HB2' ' CB ' ' A' ' 2' ' ' CYS . 72.4 m-20 -58.11 140.36 52.87 Favored 'General case' 0 C--O 1.236 0.348 0 CA-C-O 120.869 0.366 . . . . 0.0 111.123 -179.826 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.1 127.73 32.59 Favored 'General case' 0 C--N 1.326 -0.453 0 CA-C-N 115.823 -0.626 . . . . 0.0 110.972 179.903 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 125.96 -49.64 0.91 Allowed Glycine 0 N--CA 1.447 -0.604 0 N-CA-C 111.314 -0.714 . . . . 0.0 111.314 -179.522 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.482 ' HB3' HG23 ' A' ' 33' ' ' VAL . 59.9 m -89.65 113.64 25.14 Favored 'General case' 0 C--N 1.323 -0.571 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 178.947 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 44.0 p90 -65.11 145.06 56.79 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.428 -0.806 . . . . 0.0 112.777 -177.818 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 40.6 t -75.82 96.54 3.7 Favored 'General case' 0 C--N 1.326 -0.447 0 N-CA-C 108.463 -0.94 . . . . 0.0 108.463 178.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 49.7 ttp85 -79.64 123.63 84.0 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.686 -178.031 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.6 Cg_endo -70.25 158.85 55.02 Favored 'Trans proline' 0 N--CA 1.456 -0.702 0 C-N-CA 122.287 1.991 . . . . 0.0 109.536 177.515 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t70 -55.82 -52.84 62.6 Favored 'General case' 0 C--N 1.321 -0.655 0 CA-C-O 120.904 0.383 . . . . 0.0 110.703 -179.132 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -154.63 -142.33 3.43 Favored Glycine 0 N--CA 1.442 -0.966 0 C-N-CA 120.81 -0.709 . . . . 0.0 111.968 179.042 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -85.3 129.87 37.15 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.647 0 CA-C-O 121.056 0.455 . . . . 0.0 111.543 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.24 34.18 88.83 Favored Glycine 0 N--CA 1.453 -0.194 0 CA-C-N 115.504 -0.771 . . . . 0.0 113.305 179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.9 mt -125.12 136.68 60.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.416 0 N-CA-C 109.95 -0.389 . . . . 0.0 109.95 179.489 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 28.1 m -88.98 -29.47 5.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 CA-C-N 115.789 -0.641 . . . . 0.0 111.347 -179.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.27 146.85 27.55 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.926 -0.579 . . . . 0.0 110.211 179.658 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -178.03 -146.31 6.34 Favored Glycine 0 N--CA 1.444 -0.772 0 C-N-CA 120.688 -0.768 . . . . 0.0 112.084 179.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -152.62 135.02 6.27 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.664 0 CA-C-O 120.756 0.312 . . . . 0.0 110.539 179.584 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.645 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 5.3 p -69.88 145.71 51.8 Favored 'General case' 0 C--N 1.325 -0.49 0 N-CA-C 109.426 -0.583 . . . . 0.0 109.426 178.848 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.482 HG23 ' HB3' ' A' ' 18' ' ' CYS . 27.7 m . . . . . 0 C--O 1.247 0.966 0 CA-C-O 118.536 -0.745 . . . . 0.0 109.961 179.732 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.794 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 9.0 m -77.65 -28.41 51.27 Favored 'General case' 0 C--N 1.324 -0.517 0 CA-C-O 120.879 0.371 . . . . 0.0 110.783 -179.125 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.763 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -59.19 128.3 36.45 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 116.117 -0.492 . . . . 0.0 111.418 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -62.05 -37.64 94.78 Favored Glycine 0 N--CA 1.449 -0.469 0 CA-C-N 115.844 -0.616 . . . . 0.0 112.419 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.449 ' HA ' ' HD3' ' A' ' 5' ' ' LYS . 30.5 mmtm -152.85 -49.95 0.1 Allowed 'General case' 0 C--N 1.331 -0.237 0 CA-C-O 120.564 0.221 . . . . 0.0 110.719 179.656 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -160.69 179.25 8.7 Favored 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 116.45 -0.341 . . . . 0.0 110.347 -179.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 50.0 t -151.25 154.02 36.0 Favored 'General case' 0 C--N 1.322 -0.601 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.118 -179.872 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.708 ' HB3' HD23 ' A' ' 10' ' ' LEU . 4.6 m120 -134.79 132.06 38.26 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 110.117 -0.327 . . . . 0.0 110.117 179.643 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 3.6 mm? -76.68 45.27 0.4 Allowed 'General case' 0 C--N 1.329 -0.318 0 CA-C-O 121.154 0.502 . . . . 0.0 111.126 179.786 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.708 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.4 mm? -113.15 52.4 0.79 Allowed 'General case' 0 C--N 1.323 -0.565 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.045 179.886 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 73.29 45.5 30.43 Favored Glycine 0 N--CA 1.449 -0.457 0 C-N-CA 120.644 -0.789 . . . . 0.0 111.426 -179.237 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.425 HD13 ' N ' ' A' ' 13' ' ' THR . 2.9 tm? -141.08 137.45 32.86 Favored 'General case' 0 C--N 1.322 -0.594 0 N-CA-C 108.968 -0.753 . . . . 0.0 108.968 -179.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.425 ' N ' HD13 ' A' ' 12' ' ' LEU . 4.6 t -137.38 138.36 39.81 Favored 'General case' 0 C--N 1.319 -0.734 0 CA-C-N 116.33 -0.395 . . . . 0.0 110.215 -179.672 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.467 ' HB2' ' H ' ' A' ' 15' ' ' ASP . 0.8 OUTLIER -95.28 -146.81 0.27 Allowed 'General case' 0 C--N 1.32 -0.706 0 CA-C-N 115.746 -0.661 . . . . 0.0 111.313 -179.291 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.467 ' H ' ' HB2' ' A' ' 14' ' ' CYS . 1.0 OUTLIER -60.69 141.72 56.52 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.796 -0.638 . . . . 0.0 111.438 -179.298 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -63.64 127.79 32.94 Favored 'General case' 0 C--N 1.327 -0.381 0 CA-C-N 115.753 -0.658 . . . . 0.0 110.46 179.535 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.96 -39.33 2.82 Favored Glycine 0 N--CA 1.448 -0.501 0 N-CA-C 111.24 -0.744 . . . . 0.0 111.24 -179.016 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 3.5 m -88.2 74.34 8.78 Favored 'General case' 0 C--N 1.323 -0.563 0 N-CA-C 108.98 -0.748 . . . . 0.0 108.98 179.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 47.4 p90 -53.19 140.07 27.27 Favored 'General case' 0 C--N 1.325 -0.498 0 CA-C-N 115.35 -0.841 . . . . 0.0 112.349 -178.191 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.0 t -72.61 92.72 1.54 Allowed 'General case' 0 C--N 1.325 -0.468 0 CA-C-N 115.005 -0.998 . . . . 0.0 109.663 179.729 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.45 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.8 ttp180 -78.29 130.93 70.37 Favored Pre-proline 0 C--N 1.324 -0.542 0 CA-C-N 116.068 -0.515 . . . . 0.0 110.765 -179.164 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.45 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 38.1 Cg_endo -70.82 158.49 55.42 Favored 'Trans proline' 0 N--CA 1.457 -0.655 0 C-N-CA 122.143 1.895 . . . . 0.0 110.574 178.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 45.8 t0 -58.12 -53.55 57.01 Favored 'General case' 0 C--N 1.321 -0.662 0 CA-C-O 120.917 0.389 . . . . 0.0 110.359 -179.174 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.18 -143.11 3.57 Favored Glycine 0 N--CA 1.443 -0.881 0 C-N-CA 120.577 -0.821 . . . . 0.0 112.014 179.074 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.2 m -81.65 129.36 37.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.066 0.46 . . . . 0.0 111.553 -179.877 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 64.91 32.98 86.02 Favored Glycine 0 N--CA 1.452 -0.277 0 CA-C-N 115.539 -0.755 . . . . 0.0 113.33 179.518 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 25.9 mt -124.12 134.95 65.19 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.381 0 CA-C-O 121.033 0.444 . . . . 0.0 110.063 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.83 -27.54 5.37 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.698 0 CA-C-N 115.617 -0.719 . . . . 0.0 111.345 -179.229 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.45 150.38 25.34 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-N 116.04 -0.527 . . . . 0.0 109.849 179.491 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.66 -150.61 7.06 Favored Glycine 0 N--CA 1.445 -0.714 0 C-N-CA 120.635 -0.793 . . . . 0.0 112.337 -179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 9.2 p -152.79 137.86 10.52 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.626 0 CA-C-O 120.794 0.33 . . . . 0.0 110.775 -179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.763 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 43.2 m -69.4 140.78 54.19 Favored 'General case' 0 C--N 1.326 -0.417 0 N-CA-C 109.407 -0.59 . . . . 0.0 109.407 179.171 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.8 m . . . . . 0 C--O 1.249 1.053 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.018 -179.325 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.813 0 N-CA-C 111.472 -0.651 . . . . 0.0 111.472 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.4 m -85.54 -18.08 34.46 Favored 'General case' 0 C--N 1.323 -0.544 0 CA-C-O 121.233 0.54 . . . . 0.0 110.106 -179.492 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.864 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -62.44 119.28 8.82 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.635 -0.711 . . . . 0.0 112.753 -178.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -90.23 -20.19 43.06 Favored Glycine 0 N--CA 1.447 -0.61 0 N-CA-C 110.138 -1.185 . . . . 0.0 110.138 177.689 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.406 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 47.2 mtmt -150.04 167.71 25.98 Favored 'General case' 0 C--O 1.235 0.323 0 CA-C-N 114.752 -0.724 . . . . 0.0 109.263 179.775 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -64.0 145.46 55.84 Favored 'General case' 0 C--N 1.326 -0.422 0 N-CA-C 109.815 -0.439 . . . . 0.0 109.815 178.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.6 t -124.15 116.44 22.73 Favored 'General case' 0 C--N 1.322 -0.595 0 CA-C-O 120.73 0.3 . . . . 0.0 110.578 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.538 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.8 t30 -84.68 24.32 1.04 Allowed 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 116.419 -0.355 . . . . 0.0 111.27 -179.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 23.1 tp 54.75 38.35 29.98 Favored 'General case' 0 N--CA 1.467 0.389 0 CA-C-O 121.471 0.653 . . . . 0.0 110.919 -179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.419 ' HG ' ' O ' ' A' ' 8' ' ' ASN . 96.3 mt -129.02 38.01 3.99 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-N 115.849 -0.614 . . . . 0.0 109.91 179.906 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 154.61 -135.42 4.7 Favored Glycine 0 N--CA 1.444 -0.769 0 CA-C-N 115.673 -0.694 . . . . 0.0 111.7 -179.78 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.596 HD13 ' H ' ' A' ' 14' ' ' CYS . 1.1 tm? -156.58 135.88 12.14 Favored 'General case' 0 C--N 1.324 -0.529 0 N-CA-C 108.749 -0.834 . . . . 0.0 108.749 179.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.405 ' N ' HD13 ' A' ' 12' ' ' LEU . 7.2 t -148.78 47.46 1.02 Allowed 'General case' 0 C--N 1.324 -0.515 0 CA-C-O 121.894 0.854 . . . . 0.0 110.605 -178.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.596 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.7 p -161.19 -156.44 0.45 Allowed 'General case' 0 C--N 1.323 -0.559 0 CA-C-N 115.121 -0.945 . . . . 0.0 110.346 179.607 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 79.9 m-20 -69.02 146.25 52.85 Favored 'General case' 0 C--N 1.321 -0.632 0 CA-C-N 116.063 -0.517 . . . . 0.0 110.808 -179.893 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -71.68 65.44 0.49 Allowed 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.914 -0.584 . . . . 0.0 111.054 179.624 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 178.01 -28.53 0.06 OUTLIER Glycine 0 N--CA 1.447 -0.627 0 N-CA-C 111.379 -0.688 . . . . 0.0 111.379 -179.366 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.3 m -87.95 119.63 28.5 Favored 'General case' 0 N--CA 1.447 -0.575 0 N-CA-C 109.373 -0.602 . . . . 0.0 109.373 179.95 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.6 p90 -80.8 148.57 29.96 Favored 'General case' 0 C--N 1.318 -0.795 0 CA-C-N 115.347 -0.842 . . . . 0.0 112.148 -178.726 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.764 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 91.2 m -75.15 115.1 14.41 Favored 'General case' 0 C--N 1.324 -0.502 0 N-CA-C 108.649 -0.871 . . . . 0.0 108.649 177.763 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.565 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 11.9 ttp180 -90.94 131.26 37.78 Favored Pre-proline 0 C--N 1.32 -0.694 0 C-N-CA 121.017 -0.273 . . . . 0.0 110.732 -179.143 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.565 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 39.8 Cg_endo -71.11 158.19 55.65 Favored 'Trans proline' 0 N--CA 1.458 -0.617 0 C-N-CA 122.229 1.953 . . . . 0.0 111.057 178.832 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 49.9 t0 -58.24 -56.84 16.88 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 120.951 0.405 . . . . 0.0 110.62 -179.374 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.97 -142.99 3.55 Favored Glycine 0 N--CA 1.443 -0.899 0 C-N-CA 120.477 -0.868 . . . . 0.0 112.318 179.215 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.0 m -82.45 133.88 28.19 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.622 0 CA-C-O 121.074 0.464 . . . . 0.0 111.519 -179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.75 29.76 75.2 Favored Glycine 0 N--CA 1.453 -0.219 0 CA-C-N 115.348 -0.842 . . . . 0.0 113.001 179.76 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 18.1 mt -134.79 134.39 53.85 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.433 0 N-CA-C 110.017 -0.364 . . . . 0.0 110.017 179.577 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 19.2 m -93.16 -34.45 5.9 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.724 0 CA-C-N 116.029 -0.532 . . . . 0.0 110.266 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.538 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -66.26 140.96 58.18 Favored 'General case' 0 C--N 1.325 -0.461 0 CA-C-N 115.736 -0.666 . . . . 0.0 110.696 179.597 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -176.24 -140.43 3.5 Favored Glycine 0 N--CA 1.446 -0.637 0 C-N-CA 120.479 -0.867 . . . . 0.0 112.48 -179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.7 p -151.72 142.86 16.01 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 120.856 0.36 . . . . 0.0 110.487 -179.949 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.864 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 53.2 t -64.71 143.77 57.7 Favored 'General case' 0 C--N 1.325 -0.496 0 N-CA-C 109.585 -0.524 . . . . 0.0 109.585 179.432 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 23.7 m . . . . . 0 C--O 1.249 1.069 0 CA-C-O 119.182 -0.437 . . . . 0.0 112.006 -178.938 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.744 0 N-CA-C 111.585 -0.606 . . . . 0.0 111.585 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.553 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.9 m -121.66 38.94 3.98 Favored 'General case' 0 C--N 1.322 -0.603 0 CA-C-O 121.632 0.729 . . . . 0.0 109.855 -179.245 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -75.95 73.61 2.85 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.242 -0.89 . . . . 0.0 111.239 -179.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.22 -43.75 89.15 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.471 -0.786 . . . . 0.0 112.341 -179.617 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 51.5 tptt -175.06 -51.23 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.674 0.273 . . . . 0.0 110.627 179.091 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -170.22 159.13 7.17 Favored 'General case' 0 C--N 1.327 -0.374 0 CA-C-N 115.989 -0.551 . . . . 0.0 110.021 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.401 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 42.9 t -151.17 134.92 16.43 Favored 'General case' 0 C--N 1.323 -0.552 0 CA-C-O 120.797 0.332 . . . . 0.0 110.837 179.759 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.405 ' C ' ' H ' ' A' ' 10' ' ' LEU . 4.2 m120 -108.57 138.27 45.15 Favored 'General case' 0 C--N 1.32 -0.687 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 178.572 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.445 ' HG ' ' H ' ' A' ' 9' ' ' LEU . 1.5 pp -73.41 41.6 0.11 Allowed 'General case' 0 N--CA 1.467 0.38 0 CA-C-O 121.375 0.607 . . . . 0.0 111.8 -179.813 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.405 ' H ' ' C ' ' A' ' 8' ' ' ASN . 95.4 mt -129.19 29.52 5.14 Favored 'General case' 0 C--N 1.323 -0.551 0 CA-C-N 115.632 -0.713 . . . . 0.0 109.412 179.36 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 167.99 -143.49 8.2 Favored Glycine 0 N--CA 1.445 -0.702 0 CA-C-N 115.425 -0.807 . . . . 0.0 111.516 -179.797 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 83.4 mt -147.31 133.52 19.43 Favored 'General case' 0 C--N 1.326 -0.45 0 N-CA-C 110.341 -0.244 . . . . 0.0 110.341 179.64 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -167.03 42.2 0.05 OUTLIER 'General case' 0 C--N 1.326 -0.438 0 CA-C-O 121.762 0.791 . . . . 0.0 109.979 179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 56.7 m -134.85 141.14 46.3 Favored 'General case' 0 C--N 1.327 -0.385 0 CA-C-N 115.308 -0.86 . . . . 0.0 109.947 179.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.553 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 1.8 m-20 -60.6 148.3 38.75 Favored 'General case' 0 C--N 1.326 -0.454 0 O-C-N 123.49 0.494 . . . . 0.0 110.274 179.902 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -52.26 126.53 19.21 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.038 -0.528 . . . . 0.0 111.553 -179.218 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 109.62 -40.88 2.39 Favored Glycine 0 N--CA 1.447 -0.579 0 CA-C-N 115.8 -0.637 . . . . 0.0 111.629 -179.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 81.8 m -89.65 108.62 19.78 Favored 'General case' 0 C--N 1.323 -0.58 0 CA-C-O 121.078 0.466 . . . . 0.0 110.298 179.447 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 42.6 p90 -76.01 147.24 38.93 Favored 'General case' 0 C--N 1.321 -0.641 0 CA-C-N 115.982 -0.554 . . . . 0.0 110.693 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.6 t -72.1 119.34 16.16 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 109.24 -0.652 . . . . 0.0 109.24 179.528 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.554 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 12.7 ttp180 -110.33 131.77 21.86 Favored Pre-proline 0 C--N 1.324 -0.533 0 C-N-CA 120.956 -0.298 . . . . 0.0 110.962 -179.023 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.554 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.9 Cg_endo -70.64 161.52 45.77 Favored 'Trans proline' 0 N--CA 1.459 -0.52 0 C-N-CA 122.411 2.074 . . . . 0.0 111.107 178.582 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -58.97 -54.53 46.1 Favored 'General case' 0 C--N 1.326 -0.446 0 CA-C-O 120.851 0.357 . . . . 0.0 110.207 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.63 -142.0 3.33 Favored Glycine 0 N--CA 1.442 -0.941 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.848 179.009 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.1 m -84.45 130.54 35.8 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.565 0 CA-C-O 121.08 0.467 . . . . 0.0 111.6 -179.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.35 33.92 87.96 Favored Glycine 0 C--O 1.229 -0.186 0 CA-C-N 115.495 -0.775 . . . . 0.0 113.267 179.607 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 29.3 mt -125.61 136.33 61.18 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.445 0 CA-C-O 120.921 0.391 . . . . 0.0 109.982 179.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.4 m -88.56 -30.02 5.37 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.669 0 CA-C-N 115.768 -0.651 . . . . 0.0 111.369 -179.208 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -83.14 148.77 27.28 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.998 -0.546 . . . . 0.0 110.112 179.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.33 -149.4 6.52 Favored Glycine 0 N--CA 1.447 -0.573 0 C-N-CA 120.872 -0.68 . . . . 0.0 111.845 -179.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.2 p -153.06 146.56 14.77 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.608 0 CA-C-O 120.636 0.255 . . . . 0.0 110.652 179.72 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.401 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 16.5 m -66.29 137.29 56.83 Favored 'General case' 0 C--N 1.328 -0.342 0 N-CA-C 109.775 -0.454 . . . . 0.0 109.775 179.262 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.415 HG13 ' HB2' ' A' ' 21' ' ' ARG . 28.8 m . . . . . 0 C--O 1.25 1.085 0 CA-C-O 118.936 -0.554 . . . . 0.0 111.217 -179.933 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.459 -0.657 . . . . 0.0 111.459 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.57 ' SG ' ' HB3' ' A' ' 14' ' ' CYS . 20.2 p -167.01 -29.83 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.405 0 CA-C-O 120.559 0.218 . . . . 0.0 111.326 -179.609 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -54.41 126.08 21.99 Favored 'General case' 0 CA--C 1.519 -0.212 0 N-CA-C 112.056 0.391 . . . . 0.0 112.056 -179.188 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -80.08 6.75 58.72 Favored Glycine 0 N--CA 1.448 -0.515 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.065 179.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 6.7 ttpm? -179.04 -62.31 0.01 OUTLIER 'General case' 0 C--O 1.226 -0.135 0 C-N-CA 122.476 0.31 . . . . 0.0 110.627 179.324 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.559 ' HA ' HG23 ' A' ' 31' ' ' VAL . . . -179.65 163.19 1.15 Allowed 'General case' 0 C--O 1.234 0.284 0 CA-C-N 116.104 -0.498 . . . . 0.0 110.077 -179.628 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.453 ' H ' ' HA ' ' A' ' 31' ' ' VAL . 50.2 t -150.41 128.28 11.75 Favored 'General case' 0 C--N 1.328 -0.349 0 O-C-N 123.185 0.303 . . . . 0.0 110.241 179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.417 ' C ' ' H ' ' A' ' 10' ' ' LEU . 3.6 m120 -75.24 154.29 37.58 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.498 -0.319 . . . . 0.0 110.492 179.967 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.584 HD13 ' HD3' ' A' ' 22' ' ' PRO . 32.2 tp -75.43 43.96 0.25 Allowed 'General case' 0 CA--C 1.534 0.351 0 CA-C-O 121.762 0.791 . . . . 0.0 110.081 178.908 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.429 HD12 ' N ' ' A' ' 11' ' ' GLY . 1.1 pp -93.4 -14.75 26.42 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.303 -0.862 . . . . 0.0 110.08 179.758 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.429 ' N ' HD12 ' A' ' 10' ' ' LEU . . . 171.48 -124.34 1.1 Allowed Glycine 0 N--CA 1.444 -0.82 0 CA-C-N 115.337 -0.847 . . . . 0.0 111.261 179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.438 HD13 ' HA ' ' A' ' 19' ' ' PHE . 55.3 tp -157.21 130.38 7.8 Favored 'General case' 0 C--N 1.323 -0.586 0 N-CA-C 109.913 -0.402 . . . . 0.0 109.913 179.351 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.1 t -156.96 34.39 0.29 Allowed 'General case' 0 C--N 1.323 -0.562 0 CA-C-O 121.876 0.846 . . . . 0.0 109.912 -179.605 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.57 ' HB3' ' SG ' ' A' ' 2' ' ' CYS . 3.6 m -104.9 -150.5 0.43 Allowed 'General case' 0 C--N 1.323 -0.55 0 CA-C-N 115.237 -0.892 . . . . 0.0 109.773 179.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 38.0 t0 -93.77 -171.01 2.47 Favored 'General case' 0 C--N 1.324 -0.506 0 N-CA-C 109.197 -0.668 . . . . 0.0 109.197 178.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -79.11 125.4 29.37 Favored 'General case' 0 C--N 1.315 -0.901 0 CA-C-O 121.195 0.521 . . . . 0.0 111.922 -179.705 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 84.73 27.92 33.64 Favored Glycine 0 N--CA 1.452 -0.291 0 CA-C-N 115.843 -0.617 . . . . 0.0 114.323 178.405 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 7.8 p -150.34 104.35 3.23 Favored 'General case' 0 C--N 1.324 -0.504 0 CA-C-O 121.408 0.623 . . . . 0.0 110.727 178.74 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.511 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 27.5 p90 -81.35 156.56 25.41 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 115.475 -0.784 . . . . 0.0 111.817 -179.579 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.422 ' SG ' ' SG ' ' A' ' 14' ' ' CYS . 73.0 m -75.6 70.05 2.39 Favored 'General case' 0 C--N 1.327 -0.409 0 CA-C-N 115.37 -0.832 . . . . 0.0 110.071 179.056 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.511 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 8.4 ttt180 -62.82 129.9 93.44 Favored Pre-proline 0 C--N 1.323 -0.556 0 CA-C-N 115.691 -0.686 . . . . 0.0 111.934 -178.923 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.584 ' HD3' HD13 ' A' ' 9' ' ' LEU . 44.2 Cg_endo -68.11 160.43 48.77 Favored 'Trans proline' 0 C--O 1.24 0.605 0 C-N-CA 122.484 2.123 . . . . 0.0 111.083 178.17 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -58.77 -58.86 6.74 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-O 121.183 0.516 . . . . 0.0 111.049 -179.374 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -152.22 -142.4 3.49 Favored Glycine 0 N--CA 1.44 -1.083 0 C-N-CA 120.498 -0.858 . . . . 0.0 112.509 179.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 20.3 m -83.31 132.55 31.15 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 CA-C-O 121.213 0.53 . . . . 0.0 111.731 -179.565 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.0 33.18 86.55 Favored Glycine 0 N--CA 1.451 -0.33 0 CA-C-N 115.304 -0.862 . . . . 0.0 113.256 179.466 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 27.9 mt -128.52 135.09 63.35 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.5 0 CA-C-O 120.893 0.377 . . . . 0.0 110.126 179.446 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.4 m -89.11 -32.37 5.74 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.736 0 CA-C-N 115.859 -0.61 . . . . 0.0 110.904 -179.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -75.1 146.91 41.02 Favored 'General case' 0 C--N 1.325 -0.49 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.119 179.575 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . 0.52 ' O ' ' HB1' ' A' ' 6' ' ' ALA . . . -169.27 -155.09 9.57 Favored Glycine 0 N--CA 1.445 -0.759 0 C-N-CA 120.389 -0.91 . . . . 0.0 112.09 -179.89 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.559 HG23 ' HA ' ' A' ' 6' ' ' ALA . 12.9 p -152.37 143.2 15.48 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.629 0 CA-C-O 120.432 0.158 . . . . 0.0 110.875 -179.735 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.614 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 8.6 m -60.61 133.43 56.09 Favored 'General case' 0 C--O 1.235 0.326 0 N-CA-C 109.296 -0.631 . . . . 0.0 109.296 178.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 15.0 m . . . . . 0 C--O 1.25 1.104 0 CA-C-O 118.99 -0.528 . . . . 0.0 111.764 -179.736 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.664 0 N-CA-C 112.344 -0.302 . . . . 0.0 112.344 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 3.2 m -93.55 30.53 1.73 Allowed 'General case' 0 C--N 1.327 -0.375 0 CA-C-O 121.808 0.813 . . . . 0.0 110.005 -179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.923 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -121.8 138.22 54.46 Favored 'General case' 0 C--N 1.315 -0.894 0 CA-C-N 114.873 -1.058 . . . . 0.0 110.516 179.989 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -61.49 -38.41 95.73 Favored Glycine 0 N--CA 1.451 -0.329 0 C-N-CA 120.94 -0.648 . . . . 0.0 112.088 179.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.427 ' HE2' ' HB2' ' A' ' 5' ' ' LYS . 6.1 ttmm -176.11 -42.28 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.169 0 CA-C-O 120.766 0.317 . . . . 0.0 110.501 179.49 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -152.26 155.79 38.41 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.073 -179.948 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 34.4 t -150.67 135.71 17.61 Favored 'General case' 0 C--N 1.322 -0.608 0 CA-C-N 116.365 -0.379 . . . . 0.0 110.501 -179.821 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.5 m120 -97.65 134.86 40.28 Favored 'General case' 0 C--N 1.321 -0.641 0 N-CA-C 110.158 -0.312 . . . . 0.0 110.158 179.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 34.7 tp -73.08 56.2 0.44 Allowed 'General case' 0 C--N 1.328 -0.354 0 CA-C-O 121.504 0.668 . . . . 0.0 110.969 -179.858 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 94.3 mt -135.07 28.6 3.46 Favored 'General case' 0 C--N 1.322 -0.591 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 179.832 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.92 -134.99 4.0 Favored Glycine 0 N--CA 1.445 -0.749 0 CA-C-N 115.131 -0.941 . . . . 0.0 111.113 -179.463 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -162.15 143.61 10.77 Favored 'General case' 0 C--N 1.326 -0.429 0 N-CA-C 110.168 -0.308 . . . . 0.0 110.168 179.135 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.7 t -165.49 40.27 0.07 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 121.731 0.777 . . . . 0.0 109.736 -179.273 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 81.5 m -144.01 162.94 34.9 Favored 'General case' 0 C--N 1.324 -0.5 0 CA-C-N 115.319 -0.855 . . . . 0.0 110.025 179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 47.9 m-20 -53.84 142.93 22.54 Favored 'General case' 0 C--O 1.236 0.343 0 O-C-N 123.766 0.666 . . . . 0.0 111.383 -179.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.1 133.3 54.87 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 115.568 -0.742 . . . . 0.0 111.395 -179.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 103.23 -38.23 3.33 Favored Glycine 0 N--CA 1.448 -0.56 0 N-CA-C 111.407 -0.677 . . . . 0.0 111.407 -179.307 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 5.7 m -88.09 85.37 6.95 Favored 'General case' 0 C--N 1.32 -0.68 0 CA-C-O 121.449 0.643 . . . . 0.0 109.354 179.573 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 41.8 p90 -59.52 145.38 44.34 Favored 'General case' 0 C--N 1.326 -0.436 0 CA-C-N 115.108 -0.951 . . . . 0.0 112.88 -178.052 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 53.1 t -74.87 83.64 2.19 Favored 'General case' 0 C--N 1.328 -0.364 0 CA-C-N 114.823 -1.08 . . . . 0.0 109.286 178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 2.4 ttt85 -71.57 129.8 88.15 Favored Pre-proline 0 C--N 1.323 -0.572 0 CA-C-N 115.804 -0.635 . . . . 0.0 111.809 -178.261 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 55.4 Cg_endo -74.03 161.0 41.98 Favored 'Trans proline' 0 N--CA 1.459 -0.517 0 C-N-CA 122.6 2.2 . . . . 0.0 110.839 178.221 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -56.46 -57.76 10.91 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.214 0.53 . . . . 0.0 110.47 -179.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.49 -141.18 3.06 Favored Glycine 0 N--CA 1.442 -0.921 0 C-N-CA 120.416 -0.897 . . . . 0.0 112.616 179.196 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -81.71 131.09 34.66 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.548 0 CA-C-O 121.088 0.471 . . . . 0.0 111.645 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.45 29.11 74.26 Favored Glycine 0 N--CA 1.452 -0.249 0 CA-C-N 115.468 -0.787 . . . . 0.0 113.227 179.544 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.0 mt -128.17 132.46 68.38 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.907 -0.405 . . . . 0.0 109.907 179.321 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 25.8 m -89.66 -31.94 5.48 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.798 -0.637 . . . . 0.0 111.152 -179.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -77.7 144.57 37.19 Favored 'General case' 0 C--N 1.324 -0.503 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.323 179.729 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.99 -148.34 5.86 Favored Glycine 0 N--CA 1.448 -0.544 0 C-N-CA 120.744 -0.741 . . . . 0.0 111.967 -179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.6 p -153.39 134.96 5.36 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.585 0 CA-C-O 120.727 0.299 . . . . 0.0 110.717 179.554 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.923 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 85.2 m -64.53 140.7 58.89 Favored 'General case' 0 C--O 1.239 0.518 0 N-CA-C 110.064 -0.347 . . . . 0.0 110.064 179.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 18.3 m . . . . . 0 C--O 1.245 0.84 0 CA-C-O 118.37 -0.824 . . . . 0.0 111.077 179.952 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.821 0 N-CA-C 111.491 -0.643 . . . . 0.0 111.491 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.485 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 3.1 m -90.5 23.07 3.14 Favored 'General case' 0 C--N 1.325 -0.469 0 CA-C-O 121.528 0.68 . . . . 0.0 110.877 -178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.654 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -102.99 138.22 40.15 Favored 'General case' 0 C--N 1.318 -0.788 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.126 179.894 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.36 -40.46 94.57 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.822 -0.704 . . . . 0.0 111.905 179.348 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 27.3 mtpp -149.3 -53.43 0.17 Allowed 'General case' 0 C--N 1.331 -0.201 0 CA-C-O 120.779 0.323 . . . . 0.0 110.569 179.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -167.34 159.35 12.48 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.056 -0.52 . . . . 0.0 109.772 -179.627 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.477 ' SG ' HG22 ' A' ' 13' ' ' THR . 53.2 t -151.88 128.67 10.9 Favored 'General case' 0 C--N 1.325 -0.459 0 CA-C-O 120.826 0.346 . . . . 0.0 111.567 179.744 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.567 ' HB3' HD23 ' A' ' 10' ' ' LEU . 3.9 m120 -81.09 147.89 29.89 Favored 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.966 -0.561 . . . . 0.0 109.826 178.761 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.483 HD12 HD22 ' A' ' 10' ' ' LEU . 1.6 pp -74.68 31.44 0.09 Allowed 'General case' 0 CA--C 1.535 0.386 0 CA-C-O 121.101 0.477 . . . . 0.0 112.031 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.567 HD23 ' HB3' ' A' ' 8' ' ' ASN . 3.2 mm? -108.79 27.22 9.68 Favored 'General case' 0 C--N 1.325 -0.458 0 CA-C-O 121.102 0.477 . . . . 0.0 109.981 179.388 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.76 -136.27 4.51 Favored Glycine 0 N--CA 1.446 -0.696 0 C-N-CA 120.871 -0.681 . . . . 0.0 111.97 -179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.516 HD13 ' H ' ' A' ' 14' ' ' CYS . 2.0 tm? -164.93 130.15 2.64 Favored 'General case' 0 C--N 1.325 -0.471 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.961 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.477 HG22 ' SG ' ' A' ' 7' ' ' CYS . 8.1 t -149.89 50.12 0.92 Allowed 'General case' 0 C--N 1.325 -0.482 0 CA-C-O 121.872 0.844 . . . . 0.0 110.536 -179.431 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.516 ' H ' HD13 ' A' ' 12' ' ' LEU . 1.3 p -158.35 -161.75 1.04 Allowed 'General case' 0 C--N 1.323 -0.571 0 CA-C-N 115.298 -0.864 . . . . 0.0 110.481 179.491 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.485 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 68.9 m-20 -65.24 140.46 58.73 Favored 'General case' 0 C--N 1.322 -0.587 0 CA-C-N 116.116 -0.493 . . . . 0.0 111.114 -179.466 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -62.54 132.47 52.54 Favored 'General case' 0 C--N 1.326 -0.437 0 CA-C-N 115.718 -0.674 . . . . 0.0 110.785 -179.978 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.06 -35.33 5.02 Favored Glycine 0 N--CA 1.45 -0.424 0 C-N-CA 120.745 -0.74 . . . . 0.0 111.704 -179.363 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 14.1 m -87.41 78.62 8.64 Favored 'General case' 0 C--N 1.324 -0.533 0 CA-C-O 121.449 0.642 . . . . 0.0 109.652 179.702 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 37.8 p90 -57.87 146.07 33.16 Favored 'General case' 0 C--N 1.326 -0.438 0 CA-C-N 115.115 -0.948 . . . . 0.0 112.447 -178.767 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.549 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 61.0 m -72.1 86.85 1.05 Allowed 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 114.968 -1.015 . . . . 0.0 110.345 179.743 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.541 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 16.0 ttp180 -70.06 135.1 87.31 Favored Pre-proline 0 C--N 1.325 -0.489 0 CA-C-N 115.82 -0.627 . . . . 0.0 110.627 -179.442 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.541 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 30.8 Cg_endo -65.21 157.11 59.36 Favored 'Trans proline' 0 C--O 1.236 0.415 0 C-N-CA 122.354 2.036 . . . . 0.0 111.427 178.992 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -58.66 -52.34 66.11 Favored 'General case' 0 C--N 1.323 -0.563 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.471 -179.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -153.92 -142.19 3.41 Favored Glycine 0 N--CA 1.442 -0.932 0 C-N-CA 120.849 -0.691 . . . . 0.0 112.035 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -85.64 130.84 35.68 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.068 0.461 . . . . 0.0 111.552 -179.895 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.49 34.88 90.39 Favored Glycine 0 N--CA 1.453 -0.176 0 CA-C-N 115.559 -0.746 . . . . 0.0 113.214 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 30.1 mt -127.38 136.32 60.93 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.439 0 CA-C-O 120.901 0.381 . . . . 0.0 109.996 179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.466 ' HB ' HD21 ' A' ' 10' ' ' LEU . 31.0 m -88.94 -30.54 5.3 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.642 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.106 -179.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.83 147.89 33.05 Favored 'General case' 0 C--N 1.325 -0.463 0 CA-C-N 115.971 -0.559 . . . . 0.0 109.715 179.267 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.68 -149.88 6.84 Favored Glycine 0 N--CA 1.444 -0.795 0 C-N-CA 120.289 -0.958 . . . . 0.0 112.399 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 8.7 p -152.51 140.06 13.56 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.637 0 N-CA-C 110.427 -0.212 . . . . 0.0 110.427 -179.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.654 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 19.0 m -59.06 138.11 57.67 Favored 'General case' 0 C--O 1.235 0.309 0 N-CA-C 109.623 -0.51 . . . . 0.0 109.623 179.439 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.447 HG13 ' HB2' ' A' ' 21' ' ' ARG . 20.6 m . . . . . 0 C--O 1.25 1.13 0 CA-C-O 119.08 -0.486 . . . . 0.0 111.514 -179.657 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.75 0 N-CA-C 111.531 -0.628 . . . . 0.0 111.531 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.532 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.8 m -120.92 33.81 5.43 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 121.612 0.72 . . . . 0.0 109.884 -179.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.55 87.06 5.15 Favored 'General case' 0 C--N 1.323 -0.584 0 CA-C-N 115.268 -0.878 . . . . 0.0 111.43 -179.651 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -69.0 -50.46 34.44 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.812 -0.709 . . . . 0.0 111.838 179.737 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 67.3 mttm -158.85 -53.9 0.06 Allowed 'General case' 0 N--CA 1.464 0.264 0 C-N-CA 122.853 0.461 . . . . 0.0 109.824 179.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.91 171.76 12.32 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 115.724 -0.671 . . . . 0.0 109.577 179.969 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 40.2 t -151.85 143.73 23.75 Favored 'General case' 0 C--N 1.323 -0.565 0 N-CA-C 109.975 -0.38 . . . . 0.0 109.975 179.857 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -124.47 127.65 47.8 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.571 0.224 . . . . 0.0 110.427 179.732 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 27.5 tp -75.07 59.95 0.98 Allowed 'General case' 0 C--N 1.327 -0.389 0 CA-C-O 121.526 0.679 . . . . 0.0 110.128 179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 98.0 mt -134.03 -44.63 0.79 Allowed 'General case' 0 C--N 1.322 -0.613 0 CA-C-N 115.391 -0.822 . . . . 0.0 110.232 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -175.73 51.23 0.12 Allowed Glycine 0 N--CA 1.447 -0.587 0 N-CA-C 111.278 -0.729 . . . . 0.0 111.278 -179.874 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.475 HD13 ' N ' ' A' ' 13' ' ' THR . 2.4 tm? -152.17 138.31 18.29 Favored 'General case' 0 C--N 1.325 -0.482 0 N-CA-C 109.213 -0.662 . . . . 0.0 109.213 -179.379 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.475 ' N ' HD13 ' A' ' 12' ' ' LEU . 8.1 t -144.25 142.08 30.25 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 116.277 -0.419 . . . . 0.0 109.896 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -93.28 -155.59 0.45 Allowed 'General case' 0 C--N 1.321 -0.655 0 CA-C-N 116.073 -0.512 . . . . 0.0 111.139 -179.457 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.532 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 39.0 m-20 -64.71 145.58 56.01 Favored 'General case' 0 C--N 1.327 -0.382 0 CA-C-N 115.987 -0.551 . . . . 0.0 111.283 -179.508 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.31 127.33 31.44 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 115.624 -0.717 . . . . 0.0 111.054 -179.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 115.96 -42.37 1.91 Allowed Glycine 0 N--CA 1.448 -0.557 0 N-CA-C 111.012 -0.835 . . . . 0.0 111.012 -179.185 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 82.9 m -89.77 113.26 24.78 Favored 'General case' 0 N--CA 1.446 -0.647 0 N-CA-C 109.502 -0.555 . . . . 0.0 109.502 178.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 43.5 p90 -80.05 143.29 34.16 Favored 'General case' 0 C--N 1.318 -0.767 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.151 -179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.6 t -72.62 87.9 1.25 Allowed 'General case' 0 C--N 1.327 -0.408 0 N-CA-C 109.233 -0.654 . . . . 0.0 109.233 179.228 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 47.7 ttp85 -74.85 123.23 88.86 Favored Pre-proline 0 C--N 1.324 -0.523 0 CA-C-N 115.952 -0.567 . . . . 0.0 111.904 -178.188 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -70.79 157.78 57.43 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 C-N-CA 122.32 2.014 . . . . 0.0 109.213 177.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 37.7 t0 -55.53 -52.63 63.06 Favored 'General case' 0 C--N 1.318 -0.763 0 CA-C-O 120.977 0.417 . . . . 0.0 110.831 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.57 -143.36 3.64 Favored Glycine 0 N--CA 1.442 -0.929 0 C-N-CA 120.639 -0.791 . . . . 0.0 112.099 178.983 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.7 m -83.49 131.41 33.87 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 CA-C-O 121.072 0.463 . . . . 0.0 111.372 -179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 67.0 30.87 76.59 Favored Glycine 0 CA--C 1.517 0.176 0 CA-C-N 115.419 -0.809 . . . . 0.0 113.034 179.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -128.73 134.25 64.81 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.429 0 N-CA-C 109.811 -0.441 . . . . 0.0 109.811 179.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 29.3 m -89.51 -33.06 5.89 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.681 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.035 -179.646 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -78.17 145.68 35.47 Favored 'General case' 0 C--N 1.325 -0.474 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.234 179.637 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.41 -146.49 5.07 Favored Glycine 0 N--CA 1.445 -0.707 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.195 -179.899 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.1 p -151.58 141.43 15.46 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 CA-C-O 120.831 0.348 . . . . 0.0 110.671 179.906 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.467 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 35.2 t -69.14 137.42 53.34 Favored 'General case' 0 C--N 1.324 -0.526 0 CA-C-N 115.952 -0.567 . . . . 0.0 109.613 179.667 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.924 0 CA-C-O 118.542 -0.742 . . . . 0.0 111.698 -179.278 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.764 0 N-CA-C 111.263 -0.735 . . . . 0.0 111.263 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.502 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 59.9 m -92.52 -3.36 55.23 Favored 'General case' 0 C--N 1.322 -0.602 0 CA-C-O 121.01 0.433 . . . . 0.0 111.237 -178.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.758 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -80.87 132.09 35.42 Favored 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 112.054 0.391 . . . . 0.0 112.054 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -73.06 -29.52 64.6 Favored Glycine 0 N--CA 1.449 -0.479 0 N-CA-C 111.23 -0.748 . . . . 0.0 111.23 178.362 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 54.0 pttt -172.11 -45.34 0.02 OUTLIER 'General case' 0 C--O 1.227 -0.084 0 CA-C-O 120.948 0.404 . . . . 0.0 110.476 179.543 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -155.63 163.54 39.79 Favored 'General case' 0 C--N 1.327 -0.383 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.187 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 41.0 t -151.62 134.48 15.68 Favored 'General case' 0 C--N 1.327 -0.394 0 O-C-N 123.104 0.253 . . . . 0.0 110.747 -179.883 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.3 m120 -97.74 134.82 40.39 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.657 -0.497 . . . . 0.0 109.657 178.812 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 32.1 tp -73.87 54.66 0.51 Allowed 'General case' 0 C--N 1.328 -0.353 0 CA-C-O 121.492 0.663 . . . . 0.0 110.703 -179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -139.42 29.34 2.19 Favored 'General case' 0 C--N 1.323 -0.56 0 CA-C-N 115.435 -0.802 . . . . 0.0 109.037 -179.876 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 158.66 -132.02 2.96 Favored Glycine 0 N--CA 1.446 -0.646 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.284 -179.442 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 48.4 tp -160.18 138.64 10.3 Favored 'General case' 0 C--N 1.325 -0.481 0 N-CA-C 109.748 -0.464 . . . . 0.0 109.748 179.463 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.0 t -150.33 45.78 0.89 Allowed 'General case' 0 C--N 1.324 -0.523 0 CA-C-O 121.857 0.836 . . . . 0.0 110.179 -179.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.8 OUTLIER -160.31 177.89 10.16 Favored 'General case' 0 C--N 1.324 -0.506 0 CA-C-N 115.296 -0.865 . . . . 0.0 110.524 179.366 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.502 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 49.8 m-20 -57.85 148.42 25.44 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 115.447 -0.797 . . . . 0.0 111.775 -179.122 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.21 66.16 0.62 Allowed 'General case' 0 C--N 1.33 -0.251 0 CA-C-N 115.527 -0.761 . . . . 0.0 111.43 -179.988 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -167.71 -39.47 0.02 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.54 -1.024 . . . . 0.0 110.54 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.424 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 74.0 m -89.74 121.85 32.28 Favored 'General case' 0 N--CA 1.444 -0.77 0 N-CA-C 109.358 -0.608 . . . . 0.0 109.358 178.62 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 49.0 p90 -80.25 142.96 34.11 Favored 'General case' 0 C--N 1.315 -0.906 0 CA-C-N 116.034 -0.53 . . . . 0.0 110.355 179.88 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 35.8 t -73.12 114.55 11.41 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.213 -1.032 . . . . 0.0 108.213 178.822 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 41.3 ttt180 -103.44 127.76 28.92 Favored Pre-proline 0 C--N 1.321 -0.632 0 CA-C-O 120.754 0.312 . . . . 0.0 111.725 -177.953 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 49.9 Cg_endo -69.68 159.36 53.75 Favored 'Trans proline' 0 C--O 1.237 0.432 0 C-N-CA 122.707 2.271 . . . . 0.0 111.605 178.873 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 8.6 t70 -57.63 -56.98 14.89 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.738 -179.618 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.19 -140.79 2.98 Favored Glycine 0 N--CA 1.442 -0.946 0 C-N-CA 120.331 -0.938 . . . . 0.0 112.537 179.516 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.8 m -81.86 130.48 35.73 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.607 0 CA-C-O 121.194 0.521 . . . . 0.0 111.771 -179.501 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.44 31.71 81.18 Favored Glycine 0 N--CA 1.453 -0.209 0 CA-C-N 115.399 -0.818 . . . . 0.0 113.345 179.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.9 mt -129.76 133.44 64.83 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.427 0 CA-C-O 120.94 0.4 . . . . 0.0 110.011 179.367 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.2 m -89.43 -33.43 6.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.675 0 CA-C-N 115.856 -0.611 . . . . 0.0 110.945 -179.935 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -76.22 147.17 38.54 Favored 'General case' 0 C--N 1.325 -0.481 0 CA-C-N 116.253 -0.43 . . . . 0.0 110.151 179.448 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.93 -140.19 3.08 Favored Glycine 0 N--CA 1.448 -0.554 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.189 -179.769 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.0 p -151.17 138.54 13.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.078 0.466 . . . . 0.0 110.794 179.79 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.758 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 10.2 t -71.63 138.44 48.69 Favored 'General case' 0 C--N 1.323 -0.544 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 179.21 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.4 m . . . . . 0 C--O 1.25 1.118 0 N-CA-C 112.058 0.392 . . . . 0.0 112.058 -178.498 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.48 1.59 0 N-CA-C 112.236 -0.346 . . . . 0.0 112.236 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 18' ' ' CYS . 3.9 m -113.71 34.49 4.56 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-O 121.287 0.565 . . . . 0.0 110.558 -179.738 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.513 ' HB2' ' O ' ' A' ' 32' ' ' CYS . . . -92.4 114.51 27.08 Favored 'General case' 0 C--N 1.316 -0.89 0 CA-C-N 115.717 -0.674 . . . . 0.0 111.047 -179.784 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.463 ' O ' ' HG2' ' A' ' 5' ' ' LYS . . . -66.39 -46.55 77.23 Favored Glycine 0 N--CA 1.45 -0.433 0 C-N-CA 120.429 -0.891 . . . . 0.0 110.877 179.01 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.814 ' HE3' ' HA ' ' A' ' 5' ' ' LYS . 0.0 OUTLIER -158.84 -47.84 0.06 Allowed 'General case' 0 C--N 1.327 -0.377 0 C-N-CA 123.124 0.57 . . . . 0.0 109.579 178.686 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.58 -176.14 2.69 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 115.6 -0.727 . . . . 0.0 109.559 179.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 38.0 t -150.16 162.87 39.61 Favored 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 109.866 -0.42 . . . . 0.0 109.866 179.646 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.675 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.5 OUTLIER -143.49 18.83 1.87 Allowed 'General case' 0 C--N 1.324 -0.531 0 CA-C-O 121.084 0.468 . . . . 0.0 110.037 -179.206 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 19.7 tp 51.5 35.75 15.18 Favored 'General case' 0 N--CA 1.468 0.432 0 CA-C-N 115.606 -0.725 . . . . 0.0 111.337 179.179 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.8 mt -135.3 47.31 2.33 Favored 'General case' 0 C--N 1.327 -0.378 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.331 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 163.0 -143.42 8.66 Favored Glycine 0 N--CA 1.447 -0.614 0 C-N-CA 120.664 -0.779 . . . . 0.0 111.993 179.91 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 33.0 tp -145.08 56.94 1.26 Allowed 'General case' 0 C--N 1.324 -0.51 0 CA-C-O 121.426 0.631 . . . . 0.0 109.873 179.86 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.1 t -89.22 27.73 1.35 Allowed 'General case' 0 C--N 1.325 -0.473 0 CA-C-N 115.736 -0.665 . . . . 0.0 110.498 179.847 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 24.1 m -132.63 139.77 47.9 Favored 'General case' 0 C--N 1.325 -0.491 0 CA-C-N 115.624 -0.716 . . . . 0.0 109.103 179.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.422 ' HB3' ' HB3' ' A' ' 2' ' ' CYS . 14.6 t70 -73.51 177.15 5.5 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-O 120.858 0.361 . . . . 0.0 110.724 -179.579 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -66.15 132.5 48.61 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-O 121.203 0.525 . . . . 0.0 112.283 -179.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 96.7 -38.2 3.18 Favored Glycine 0 N--CA 1.45 -0.405 0 CA-C-N 115.784 -0.644 . . . . 0.0 112.426 179.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.461 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.4 m -89.38 103.39 16.03 Favored 'General case' 0 C--N 1.318 -0.791 0 CA-C-O 121.084 0.469 . . . . 0.0 110.744 -179.888 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -74.76 149.15 39.86 Favored 'General case' 0 C--N 1.324 -0.514 0 CA-C-N 115.902 -0.59 . . . . 0.0 111.52 -179.672 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 30.3 t -73.76 97.41 2.71 Favored 'General case' 0 C--N 1.324 -0.514 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 178.3 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 31.0 ttt-85 -83.64 121.64 76.38 Favored Pre-proline 0 C--N 1.321 -0.669 0 CA-C-N 116.302 -0.408 . . . . 0.0 111.633 -178.234 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -68.81 156.3 65.88 Favored 'Trans proline' 0 N--CA 1.458 -0.577 0 C-N-CA 122.659 2.24 . . . . 0.0 110.463 178.101 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 51.1 t0 -54.54 -57.17 12.41 Favored 'General case' 0 C--N 1.321 -0.672 0 CA-C-O 120.962 0.411 . . . . 0.0 110.871 -179.156 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.14 -141.79 3.22 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.568 -0.825 . . . . 0.0 112.596 179.286 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.0 m -79.59 131.27 34.61 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.633 0 CA-C-O 121.246 0.546 . . . . 0.0 111.84 -179.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.0 30.49 77.11 Favored Glycine 0 N--CA 1.453 -0.233 0 CA-C-N 115.281 -0.872 . . . . 0.0 113.161 179.501 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.6 mt -131.21 132.78 63.08 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.45 0 CA-C-O 120.912 0.387 . . . . 0.0 110.104 179.502 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.434 HG23 HD21 ' A' ' 8' ' ' ASN . 14.8 m -92.04 -31.33 4.8 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.709 0 CA-C-N 115.784 -0.643 . . . . 0.0 110.668 179.83 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.675 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.42 143.13 50.23 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.003 -0.544 . . . . 0.0 110.14 179.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -172.49 -146.08 5.23 Favored Glycine 0 N--CA 1.447 -0.607 0 C-N-CA 120.453 -0.88 . . . . 0.0 112.448 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 15.0 p -152.81 143.4 15.11 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.679 0 CA-C-O 120.632 0.253 . . . . 0.0 110.554 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.513 ' O ' ' HB2' ' A' ' 3' ' ' ALA . 4.6 m -66.66 139.31 57.85 Favored 'General case' 0 C--N 1.324 -0.51 0 N-CA-C 109.456 -0.572 . . . . 0.0 109.456 179.401 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 31.5 m . . . . . 0 C--O 1.246 0.875 0 CA-C-O 118.51 -0.757 . . . . 0.0 111.111 -179.889 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.72 0 N-CA-C 111.305 -0.718 . . . . 0.0 111.305 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.619 ' HB2' ' SG ' ' A' ' 14' ' ' CYS . 48.1 m -91.13 -17.64 25.8 Favored 'General case' 0 C--N 1.324 -0.525 0 CA-C-O 121.005 0.431 . . . . 0.0 110.66 -179.39 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.827 ' HB2' ' HB3' ' A' ' 32' ' ' CYS . . . -63.28 127.11 29.8 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.858 -179.455 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -71.92 -28.94 67.82 Favored Glycine 0 N--CA 1.449 -0.441 0 CA-C-N 115.695 -0.684 . . . . 0.0 111.683 179.123 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.4 tttm -168.9 -43.24 0.02 OUTLIER 'General case' 0 C--N 1.331 -0.216 0 CA-C-O 120.761 0.315 . . . . 0.0 110.533 179.751 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.39 177.33 7.58 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.294 -0.412 . . . . 0.0 110.354 -179.639 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 45.1 t -151.76 133.43 14.79 Favored 'General case' 0 C--N 1.324 -0.518 0 N-CA-C 109.753 -0.462 . . . . 0.0 109.753 179.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.498 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 0.7 OUTLIER -109.15 23.78 14.04 Favored 'General case' 0 C--N 1.324 -0.534 0 C-N-CA 120.79 -0.364 . . . . 0.0 111.186 -179.573 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 7.2 tt 69.47 -50.58 0.61 Allowed 'General case' 0 N--CA 1.472 0.641 0 O-C-N 123.987 0.805 . . . . 0.0 111.155 -179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 60.0 mt -75.17 54.4 0.69 Allowed 'General case' 0 C--N 1.326 -0.419 0 C-N-CA 122.98 0.512 . . . . 0.0 111.543 -179.862 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 175.94 134.95 2.03 Favored Glycine 0 N--CA 1.445 -0.711 0 C-N-CA 120.51 -0.852 . . . . 0.0 112.278 -179.968 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.44 48.89 1.35 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-O 121.236 0.541 . . . . 0.0 110.131 179.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -85.27 50.38 1.94 Allowed 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.063 -179.505 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . 0.619 ' SG ' ' HB2' ' A' ' 2' ' ' CYS . 1.7 t -164.88 160.91 19.85 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.108 179.784 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 80.7 m-20 -73.68 153.89 39.91 Favored 'General case' 0 C--N 1.321 -0.65 0 CA-C-N 115.501 -0.772 . . . . 0.0 110.808 179.961 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -72.49 67.25 0.73 Allowed 'General case' 0 C--N 1.328 -0.359 0 CA-C-N 115.917 -0.583 . . . . 0.0 111.423 179.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -172.15 -39.88 0.04 OUTLIER Glycine 0 N--CA 1.446 -0.645 0 N-CA-C 110.749 -0.94 . . . . 0.0 110.749 -179.944 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.416 ' HB2' ' HB2' ' A' ' 2' ' ' CYS . 87.9 m -91.73 122.27 34.13 Favored 'General case' 0 N--CA 1.446 -0.644 0 N-CA-C 109.281 -0.637 . . . . 0.0 109.281 178.513 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.9 p90 -80.37 141.72 35.11 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.887 -179.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 46.0 t -74.29 114.74 13.0 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 179.02 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.496 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 9.6 ttp180 -97.8 129.8 30.45 Favored Pre-proline 0 C--N 1.325 -0.483 0 CA-C-O 120.765 0.316 . . . . 0.0 110.995 -178.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.496 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 51.7 Cg_endo -74.15 160.18 42.96 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.45 2.1 . . . . 0.0 110.777 178.391 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 46.5 t0 -59.75 -54.05 50.78 Favored 'General case' 0 C--N 1.321 -0.638 0 CA-C-O 120.938 0.399 . . . . 0.0 110.274 -179.526 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -155.78 -143.2 3.61 Favored Glycine 0 N--CA 1.442 -0.918 0 C-N-CA 120.567 -0.825 . . . . 0.0 112.147 179.12 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.1 m -83.02 132.09 32.18 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.028 0.442 . . . . 0.0 111.518 -179.772 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.16 32.45 82.31 Favored Glycine 0 N--CA 1.452 -0.263 0 CA-C-N 115.445 -0.798 . . . . 0.0 113.272 179.576 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 20.9 mt -133.0 133.7 58.55 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.483 0 N-CA-C 110.116 -0.327 . . . . 0.0 110.116 179.471 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.6 m -89.87 -33.61 6.15 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.769 0 CA-C-N 116.119 -0.491 . . . . 0.0 110.402 179.495 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.498 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.1 141.75 50.81 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.642 -0.708 . . . . 0.0 110.404 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.29 -139.06 3.17 Favored Glycine 0 N--CA 1.447 -0.619 0 C-N-CA 120.676 -0.773 . . . . 0.0 112.423 -179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.1 p -151.47 138.26 12.86 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.671 0 CA-C-O 121.064 0.459 . . . . 0.0 110.558 179.791 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.827 ' HB3' ' HB2' ' A' ' 3' ' ' ALA . 29.3 t -75.77 145.16 40.97 Favored 'General case' 0 C--N 1.322 -0.62 0 N-CA-C 109.333 -0.617 . . . . 0.0 109.333 179.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.6 m . . . . . 0 C--O 1.252 1.225 0 N-CA-C 112.105 0.409 . . . . 0.0 112.105 -178.916 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.483 1.816 0 N-CA-C 111.796 -0.522 . . . . 0.0 111.796 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 75.1 m -79.23 -25.34 42.64 Favored 'General case' 0 C--N 1.327 -0.398 0 CA-C-O 120.695 0.283 . . . . 0.0 111.552 -179.283 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.732 ' HB2' ' HB2' ' A' ' 32' ' ' CYS . . . -69.53 126.53 30.03 Favored 'General case' 0 C--N 1.329 -0.31 0 C-N-CA 120.985 -0.286 . . . . 0.0 111.024 -179.817 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -67.48 -38.76 91.04 Favored Glycine 0 N--CA 1.453 -0.233 0 C-N-CA 120.817 -0.706 . . . . 0.0 112.109 179.793 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 12.6 mmmm -148.61 -43.36 0.15 Allowed 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.604 0.24 . . . . 0.0 110.597 179.59 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -163.17 172.53 14.69 Favored 'General case' 0 C--N 1.327 -0.388 0 CA-C-N 116.269 -0.423 . . . . 0.0 110.258 -179.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.5 t -151.35 146.18 25.82 Favored 'General case' 0 C--N 1.323 -0.578 0 N-CA-C 109.825 -0.435 . . . . 0.0 109.825 179.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -124.68 141.58 52.0 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 109.747 -0.464 . . . . 0.0 109.747 179.636 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 97.2 mt -73.56 45.96 0.19 Allowed 'General case' 0 C--N 1.328 -0.366 0 CA-C-O 121.281 0.562 . . . . 0.0 110.809 179.5 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . 0.416 ' H ' ' HG ' ' A' ' 10' ' ' LEU . 0.7 OUTLIER -86.13 43.49 1.06 Allowed 'General case' 0 C--N 1.324 -0.521 0 CA-C-N 115.765 -0.652 . . . . 0.0 111.057 179.929 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 71.68 37.98 61.39 Favored Glycine 0 N--CA 1.45 -0.384 0 CA-C-N 115.85 -0.614 . . . . 0.0 111.662 -179.541 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 8.9 tt -158.06 149.03 20.92 Favored 'General case' 0 C--N 1.327 -0.4 0 N-CA-C 109.713 -0.477 . . . . 0.0 109.713 -179.475 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.4 t -152.35 153.53 33.82 Favored 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 109.433 -0.58 . . . . 0.0 109.433 -179.984 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 75.9 m -68.73 179.37 1.78 Allowed 'General case' 0 C--N 1.325 -0.479 0 CA-C-N 116.429 -0.35 . . . . 0.0 111.207 -179.606 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 34.7 m-20 -49.28 151.51 1.44 Allowed 'General case' 0 C--O 1.237 0.396 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 -179.111 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -54.53 123.26 12.56 Favored 'General case' 0 C--N 1.331 -0.238 0 CA-C-N 115.194 -0.912 . . . . 0.0 111.404 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 119.25 -49.65 0.86 Allowed Glycine 0 N--CA 1.445 -0.753 0 N-CA-C 110.52 -1.032 . . . . 0.0 110.52 -179.064 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.671 ' HA ' HG23 ' A' ' 33' ' ' VAL . 2.4 p -101.74 67.69 1.12 Allowed 'General case' 0 C--N 1.322 -0.624 0 CA-C-O 121.943 0.878 . . . . 0.0 110.031 178.475 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 33.1 p90 -57.78 148.88 23.7 Favored 'General case' 0 C--N 1.319 -0.748 0 CA-C-N 114.075 -1.42 . . . . 0.0 112.424 -179.158 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.2 t -72.85 90.29 1.44 Allowed 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 115.371 -0.831 . . . . 0.0 109.176 178.959 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 9.7 ttp180 -75.31 129.84 81.44 Favored Pre-proline 0 C--N 1.325 -0.475 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.058 -178.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -71.28 158.24 55.01 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.172 1.914 . . . . 0.0 110.604 178.21 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.8 t0 -58.18 -53.91 52.97 Favored 'General case' 0 C--N 1.32 -0.712 0 CA-C-O 120.93 0.395 . . . . 0.0 110.464 -179.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.43 -143.19 3.59 Favored Glycine 0 N--CA 1.442 -0.954 0 C-N-CA 120.609 -0.805 . . . . 0.0 112.054 179.105 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.46 129.91 36.72 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.659 0 CA-C-O 121.076 0.465 . . . . 0.0 111.543 -179.916 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 65.12 32.95 85.71 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.472 -0.785 . . . . 0.0 113.385 179.563 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 23.2 mt -126.5 133.78 67.87 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.43 0 CA-C-O 120.91 0.386 . . . . 0.0 110.053 179.337 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 31.2 m -89.17 -27.61 5.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.683 0 CA-C-N 115.787 -0.642 . . . . 0.0 111.196 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.37 145.73 30.68 Favored 'General case' 0 C--N 1.325 -0.489 0 CA-C-N 116.045 -0.525 . . . . 0.0 110.095 179.476 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -171.36 -147.5 5.69 Favored Glycine 0 N--CA 1.444 -0.787 0 C-N-CA 120.855 -0.688 . . . . 0.0 112.323 -179.834 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 7.2 p -153.14 136.73 8.14 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.564 0 CA-C-O 120.76 0.314 . . . . 0.0 111.098 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.732 ' HB2' ' HB2' ' A' ' 3' ' ' ALA . 94.8 m -68.81 135.37 51.05 Favored 'General case' 0 C--N 1.328 -0.328 0 N-CA-C 109.449 -0.575 . . . . 0.0 109.449 178.494 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.671 HG23 ' HA ' ' A' ' 18' ' ' CYS . 29.9 m . . . . . 0 C--O 1.255 1.365 0 CA-C-O 118.968 -0.539 . . . . 0.0 111.213 -179.946 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.484 1.842 0 N-CA-C 111.417 -0.673 . . . . 0.0 111.417 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 1.8 m -102.82 24.99 9.81 Favored 'General case' 0 C--N 1.325 -0.468 0 CA-C-O 121.291 0.567 . . . . 0.0 110.59 -179.034 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.809 ' HA ' ' SG ' ' A' ' 32' ' ' CYS . . . -72.7 102.99 3.47 Favored 'General case' 0 C--N 1.32 -0.676 0 CA-C-N 115.225 -0.898 . . . . 0.0 110.737 -179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.4 ' C ' ' HG3' ' A' ' 5' ' ' LYS . . . -74.06 -41.56 39.55 Favored Glycine 0 N--CA 1.45 -0.415 0 C-N-CA 120.594 -0.813 . . . . 0.0 112.172 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.485 ' HE3' ' HB2' ' A' ' 5' ' ' LYS . 22.9 mtmt -153.19 -61.82 0.15 Allowed 'General case' 0 C--N 1.328 -0.329 0 CA-C-O 121.744 0.783 . . . . 0.0 109.159 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -175.71 166.93 3.17 Favored 'General case' 0 C--N 1.327 -0.406 0 CA-C-N 114.133 -1.394 . . . . 0.0 107.495 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 48.7 t -150.46 122.7 8.35 Favored 'General case' 0 C--N 1.321 -0.668 0 C-N-CA 120.428 -0.509 . . . . 0.0 110.836 -179.767 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.461 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.1 t30 -86.89 19.15 3.12 Favored 'General case' 0 C--N 1.327 -0.402 0 CA-C-N 116.631 -0.259 . . . . 0.0 110.834 -179.642 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 52.2 tp 71.08 -46.33 0.64 Allowed 'General case' 0 N--CA 1.47 0.569 0 C-N-CA 123.596 0.758 . . . . 0.0 111.004 -178.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 55.4 mt -78.53 48.74 0.81 Allowed 'General case' 0 C--N 1.324 -0.502 0 CA-C-N 116.007 -0.542 . . . . 0.0 111.119 179.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 173.93 141.22 3.48 Favored Glycine 0 N--CA 1.446 -0.644 0 C-N-CA 120.985 -0.626 . . . . 0.0 111.61 -179.552 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -100.23 122.31 42.84 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.314 -0.624 . . . . 0.0 109.314 179.815 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.7 t -156.37 30.6 0.33 Allowed 'General case' 0 C--N 1.318 -0.772 0 CA-C-O 121.597 0.713 . . . . 0.0 109.74 179.831 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 44.4 m -143.37 -179.54 6.47 Favored 'General case' 0 C--N 1.324 -0.513 0 CA-C-N 115.168 -0.923 . . . . 0.0 109.209 179.741 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 16.7 t0 -74.54 169.89 16.84 Favored 'General case' 0 C--O 1.236 0.374 0 CA-C-O 121.415 0.626 . . . . 0.0 111.213 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -76.19 140.21 41.59 Favored 'General case' 0 C--N 1.319 -0.758 0 CA-C-N 115.16 -0.927 . . . . 0.0 111.727 -179.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 89.59 -28.53 6.91 Favored Glycine 0 N--CA 1.452 -0.266 0 C-N-CA 120.71 -0.757 . . . . 0.0 112.638 179.544 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 2.7 m -86.71 83.86 7.5 Favored 'General case' 0 C--N 1.319 -0.739 0 CA-C-O 121.469 0.652 . . . . 0.0 109.567 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.3 p90 -57.88 144.34 39.33 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 114.908 -1.042 . . . . 0.0 112.35 -178.308 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . 0.625 ' HA ' ' HA ' ' A' ' 32' ' ' CYS . 72.9 m -75.19 91.11 2.59 Favored 'General case' 0 C--N 1.324 -0.52 0 CA-C-N 115.299 -0.864 . . . . 0.0 109.074 178.455 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.0 ttt-85 -69.64 122.21 85.02 Favored Pre-proline 0 C--N 1.321 -0.664 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.168 -178.764 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -67.08 156.93 64.16 Favored 'Trans proline' 0 N--CA 1.462 -0.346 0 C-N-CA 122.867 2.378 . . . . 0.0 111.03 178.705 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.1 t70 -52.89 -57.76 9.2 Favored 'General case' 0 C--O 1.238 0.458 0 O-C-N 123.381 0.426 . . . . 0.0 111.002 -179.249 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.5 -140.17 2.83 Favored Glycine 0 N--CA 1.44 -1.039 0 C-N-CA 120.415 -0.898 . . . . 0.0 112.749 179.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 18.6 m -80.13 134.15 28.1 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.581 0 CA-C-O 121.176 0.512 . . . . 0.0 111.907 -179.391 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.98 29.49 74.69 Favored Glycine 0 C--O 1.228 -0.256 0 CA-C-N 115.251 -0.886 . . . . 0.0 112.884 179.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 19.3 mt -134.88 136.89 51.6 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.448 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.727 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 27.6 m -99.89 -29.6 3.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.741 0 CA-C-O 121.192 0.52 . . . . 0.0 110.388 179.603 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.461 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -71.68 140.66 49.73 Favored 'General case' 0 C--N 1.326 -0.44 0 CA-C-N 115.602 -0.726 . . . . 0.0 110.755 179.807 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.5 -140.58 3.33 Favored Glycine 0 N--CA 1.446 -0.652 0 C-N-CA 120.557 -0.83 . . . . 0.0 112.461 179.896 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 13.6 p -152.29 142.72 15.4 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.643 0 CA-C-O 120.633 0.254 . . . . 0.0 110.561 179.915 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.809 ' SG ' ' HA ' ' A' ' 3' ' ' ALA . 1.2 p -66.02 139.71 58.23 Favored 'General case' 0 C--N 1.324 -0.51 0 CA-C-N 116.477 -0.329 . . . . 0.0 110.607 179.608 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 26.8 m . . . . . 0 C--O 1.247 0.925 0 CA-C-O 118.261 -0.876 . . . . 0.0 111.937 -179.16 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.727 0 N-CA-C 111.555 -0.618 . . . . 0.0 111.555 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.523 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 31.8 m -114.9 33.66 5.27 Favored 'General case' 0 C--N 1.323 -0.55 0 CA-C-O 121.581 0.705 . . . . 0.0 109.93 -179.528 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.51 82.88 3.93 Favored 'General case' 0 C--N 1.324 -0.532 0 CA-C-N 115.315 -0.857 . . . . 0.0 111.434 -179.532 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -66.88 -43.16 92.17 Favored Glycine 0 N--CA 1.451 -0.309 0 CA-C-N 115.727 -0.67 . . . . 0.0 111.863 179.783 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.5 tttm -179.59 -45.79 0.01 OUTLIER 'General case' 0 C--N 1.332 -0.153 0 CA-C-O 121.024 0.44 . . . . 0.0 110.133 179.334 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -166.36 155.47 11.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 115.752 -0.658 . . . . 0.0 110.034 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 49.7 t -151.49 125.97 9.47 Favored 'General case' 0 C--N 1.323 -0.583 0 CA-C-N 116.493 -0.321 . . . . 0.0 110.394 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 4.5 m120 -88.33 139.62 30.31 Favored 'General case' 0 C--N 1.322 -0.63 0 N-CA-C 109.648 -0.501 . . . . 0.0 109.648 179.045 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 31.5 tp -71.62 55.27 0.25 Allowed 'General case' 0 C--N 1.328 -0.339 0 CA-C-O 121.347 0.594 . . . . 0.0 111.182 -179.573 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 92.3 mt -141.75 31.44 1.64 Allowed 'General case' 0 C--N 1.323 -0.557 0 CA-C-N 115.762 -0.654 . . . . 0.0 109.272 179.92 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 164.4 -139.93 6.14 Favored Glycine 0 N--CA 1.446 -0.683 0 CA-C-N 115.523 -0.762 . . . . 0.0 111.946 -179.89 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.417 HD22 ' HA ' ' A' ' 12' ' ' LEU . 0.4 OUTLIER -163.08 73.7 0.35 Allowed 'General case' 0 C--N 1.326 -0.443 0 N-CA-C 108.797 -0.816 . . . . 0.0 108.797 179.986 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -82.1 52.6 2.03 Favored 'General case' 0 CA--C 1.538 0.511 0 CA-C-O 121.407 0.623 . . . . 0.0 111.983 -178.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 0.7 OUTLIER -161.73 -176.33 5.21 Favored 'General case' 0 C--N 1.325 -0.5 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.697 178.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.523 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 44.0 m-20 -60.75 145.99 47.57 Favored 'General case' 0 C--N 1.326 -0.455 0 CA-C-N 115.779 -0.646 . . . . 0.0 111.5 -178.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -69.06 72.1 0.26 Allowed 'General case' 0 C--N 1.331 -0.22 0 CA-C-N 115.524 -0.762 . . . . 0.0 111.581 -179.846 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.29 -38.24 0.05 OUTLIER Glycine 0 N--CA 1.447 -0.629 0 N-CA-C 110.817 -0.913 . . . . 0.0 110.817 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 60.0 m -89.65 121.84 32.21 Favored 'General case' 0 N--CA 1.444 -0.764 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 178.947 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.6 p90 -78.87 140.6 38.1 Favored 'General case' 0 C--N 1.316 -0.856 0 CA-C-N 116.065 -0.516 . . . . 0.0 110.275 179.943 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 41.1 t -72.13 106.05 4.21 Favored 'General case' 0 C--N 1.322 -0.629 0 N-CA-C 108.512 -0.921 . . . . 0.0 108.512 179.219 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttp85 -92.67 125.15 56.7 Favored Pre-proline 0 C--N 1.321 -0.654 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.775 -177.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -68.45 157.91 59.87 Favored 'Trans proline' 0 N--CA 1.457 -0.673 0 C-N-CA 122.269 1.98 . . . . 0.0 109.465 177.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 44.1 t0 -54.87 -55.28 32.15 Favored 'General case' 0 C--N 1.321 -0.669 0 CA-C-O 120.96 0.41 . . . . 0.0 110.76 -178.811 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -159.33 -142.25 3.34 Favored Glycine 0 N--CA 1.442 -0.957 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.218 179.047 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.24 131.0 34.83 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.614 0 CA-C-O 121.063 0.459 . . . . 0.0 111.444 -179.825 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.13 32.03 81.09 Favored Glycine 0 CA--C 1.518 0.239 0 CA-C-N 115.398 -0.819 . . . . 0.0 113.275 179.513 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.1 mt -128.64 134.69 64.05 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.402 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 179.303 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 22.6 m -89.41 -33.53 6.21 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.628 0 CA-C-N 115.973 -0.558 . . . . 0.0 111.16 -179.522 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -80.23 148.85 30.65 Favored 'General case' 0 C--N 1.323 -0.553 0 CA-C-N 116.3 -0.409 . . . . 0.0 110.026 179.54 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -170.61 -143.93 4.15 Favored Glycine 0 N--CA 1.448 -0.557 0 C-N-CA 120.524 -0.846 . . . . 0.0 112.292 -179.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 11.3 p -152.3 139.72 13.48 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.528 0 CA-C-O 120.864 0.364 . . . . 0.0 110.684 179.68 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 8.2 t -69.55 133.97 48.27 Favored 'General case' 0 C--N 1.327 -0.387 0 N-CA-C 108.86 -0.793 . . . . 0.0 108.86 179.357 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 27.0 m . . . . . 0 C--O 1.247 0.951 0 CA-C-O 118.599 -0.715 . . . . 0.0 111.846 -178.766 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.737 0 N-CA-C 111.741 -0.543 . . . . 0.0 111.741 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.452 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 8.8 m -126.61 39.18 3.98 Favored 'General case' 0 C--N 1.326 -0.448 0 CA-C-O 121.481 0.658 . . . . 0.0 109.949 -179.452 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -78.47 76.56 4.97 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 115.279 -0.873 . . . . 0.0 111.048 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -56.95 -42.91 92.93 Favored Glycine 0 C--O 1.236 0.245 0 CA-C-N 115.371 -0.831 . . . . 0.0 112.26 -179.754 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 2.0 tppm? -172.85 -55.36 0.02 OUTLIER 'General case' 0 C--N 1.327 -0.372 0 CA-C-O 120.494 0.188 . . . . 0.0 110.518 179.131 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -168.17 171.71 9.23 Favored 'General case' 0 C--N 1.327 -0.391 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.4 -179.842 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 39.0 t -149.89 158.28 44.01 Favored 'General case' 0 C--N 1.321 -0.654 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.386 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.696 ' HA ' ' HA ' ' A' ' 29' ' ' ALA . 2.0 t30 -137.96 27.32 2.68 Favored 'General case' 0 C--N 1.322 -0.624 0 C-N-CA 120.251 -0.579 . . . . 0.0 110.687 -179.009 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 20.0 tp 54.51 45.21 27.48 Favored 'General case' 0 N--CA 1.465 0.325 0 CA-C-N 115.569 -0.742 . . . . 0.0 111.198 179.738 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 1.3 pp -155.91 34.77 0.35 Allowed 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.063 -0.517 . . . . 0.0 111.206 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 179.94 132.83 1.88 Allowed Glycine 0 N--CA 1.446 -0.691 0 C-N-CA 120.302 -0.952 . . . . 0.0 112.307 179.63 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.707 ' H ' HD13 ' A' ' 12' ' ' LEU . 0.0 OUTLIER -86.79 46.14 1.33 Allowed 'General case' 0 C--N 1.324 -0.532 0 CA-C-O 121.078 0.466 . . . . 0.0 111.0 179.783 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 9.3 t -85.77 37.36 0.7 Allowed 'General case' 0 C--N 1.326 -0.43 0 CA-C-O 121.401 0.619 . . . . 0.0 111.064 -179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 79.9 m -144.97 137.95 26.48 Favored 'General case' 0 C--N 1.325 -0.476 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.764 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.452 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 40.4 m-20 -58.8 152.3 19.42 Favored 'General case' 0 C--O 1.237 0.397 0 CA-C-O 121.281 0.562 . . . . 0.0 112.074 -178.882 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -53.66 134.96 41.55 Favored 'General case' 0 C--N 1.331 -0.215 0 CA-C-N 115.108 -0.951 . . . . 0.0 111.563 -179.561 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 102.88 -38.89 2.99 Favored Glycine 0 N--CA 1.448 -0.539 0 N-CA-C 111.113 -0.795 . . . . 0.0 111.113 -179.173 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . 0.425 ' HA ' ' CG2' ' A' ' 33' ' ' VAL . 62.9 m -88.92 79.61 7.29 Favored 'General case' 0 C--N 1.323 -0.573 0 CA-C-O 121.295 0.569 . . . . 0.0 110.097 179.27 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 0.432 ' CE1' ' HB2' ' A' ' 21' ' ' ARG . 37.7 p90 -60.54 149.18 35.43 Favored 'General case' 0 C--N 1.322 -0.628 0 CA-C-N 115.252 -0.885 . . . . 0.0 112.125 -179.111 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 44.4 t -71.58 79.26 0.8 Allowed 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 115.551 -0.75 . . . . 0.0 109.186 178.957 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.432 ' HB2' ' CE1' ' A' ' 19' ' ' PHE . 27.6 ttp180 -67.74 124.16 88.68 Favored Pre-proline 0 C--N 1.32 -0.709 0 CA-C-N 115.079 -0.964 . . . . 0.0 111.568 -178.333 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 67.6 Cg_endo -74.32 163.53 36.15 Favored 'Trans proline' 0 C--O 1.235 0.353 0 C-N-CA 123.114 2.543 . . . . 0.0 112.34 179.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 7.3 t70 -60.25 -51.51 69.25 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 115.719 -0.673 . . . . 0.0 110.545 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -160.66 -142.26 3.34 Favored Glycine 0 N--CA 1.44 -1.05 0 C-N-CA 120.566 -0.826 . . . . 0.0 112.406 179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.04 132.15 32.22 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.632 0 CA-C-O 121.162 0.506 . . . . 0.0 111.671 -179.655 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.86 30.71 76.53 Favored Glycine 0 N--CA 1.452 -0.258 0 CA-C-N 115.382 -0.826 . . . . 0.0 113.093 179.513 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 22.2 mt -131.62 135.38 59.14 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.472 0 N-CA-C 109.874 -0.417 . . . . 0.0 109.874 179.538 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 24.0 m -91.94 -33.73 5.76 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.672 0 CA-C-O 121.181 0.515 . . . . 0.0 110.414 179.815 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . 0.696 ' HA ' ' HA ' ' A' ' 8' ' ' ASN . . . -69.3 141.07 54.39 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 115.685 -0.689 . . . . 0.0 110.764 179.812 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -177.49 -146.62 6.34 Favored Glycine 0 N--CA 1.45 -0.397 0 C-N-CA 120.516 -0.849 . . . . 0.0 112.701 179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.417 HG13 HH21 ' A' ' 21' ' ' ARG . 7.7 p -153.16 132.71 3.46 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.588 0 CA-C-O 120.76 0.315 . . . . 0.0 110.643 179.544 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 81.0 m -59.05 146.77 37.19 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.871 179.861 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.425 ' CG2' ' HA ' ' A' ' 18' ' ' CYS . 27.6 m . . . . . 0 C--O 1.249 1.028 0 CA-C-O 119.093 -0.48 . . . . 0.0 111.491 -179.57 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.482 1.715 0 N-CA-C 111.641 -0.584 . . . . 0.0 111.641 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.451 ' HB3' ' HB2' ' A' ' 15' ' ' ASP . 8.3 m -123.77 40.43 3.73 Favored 'General case' 0 C--N 1.325 -0.494 0 CA-C-O 121.497 0.665 . . . . 0.0 109.638 -179.532 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.29 75.6 1.85 Allowed 'General case' 0 C--N 1.321 -0.639 0 CA-C-N 115.249 -0.887 . . . . 0.0 111.621 -179.315 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -55.47 -43.48 85.34 Favored Glycine 0 N--CA 1.452 -0.238 0 CA-C-N 115.558 -0.747 . . . . 0.0 111.971 179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 1.7 tppm? -178.04 -52.7 0.01 OUTLIER 'General case' 0 C--N 1.331 -0.231 0 CA-C-O 120.565 0.222 . . . . 0.0 110.461 178.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -169.19 158.51 8.37 Favored 'General case' 0 C--N 1.327 -0.383 0 N-CA-C 109.604 -0.517 . . . . 0.0 109.604 -179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.457 ' HB2' ' SG ' ' A' ' 32' ' ' CYS . 49.7 t -151.19 134.32 15.97 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-O 120.763 0.316 . . . . 0.0 111.025 179.825 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 3.9 m120 -105.61 139.73 39.76 Favored 'General case' 0 C--N 1.321 -0.643 0 N-CA-C 109.05 -0.722 . . . . 0.0 109.05 178.507 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.407 HD11 HG12 ' A' ' 28' ' ' VAL . 3.6 pp -63.0 -10.68 14.75 Favored 'General case' 0 N--CA 1.465 0.307 0 CA-C-O 121.034 0.445 . . . . 0.0 111.221 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 96.1 mt -81.26 38.17 0.47 Allowed 'General case' 0 C--N 1.327 -0.386 0 CA-C-N 115.935 -0.575 . . . . 0.0 110.738 178.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 159.73 -138.98 5.87 Favored Glycine 0 N--CA 1.446 -0.651 0 N-CA-C 111.517 -0.633 . . . . 0.0 111.517 -179.651 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . . . . . . . . . 2.5 tm? -167.29 131.98 1.95 Allowed 'General case' 0 C--N 1.326 -0.431 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 179.698 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 6.8 t -158.66 47.24 0.33 Allowed 'General case' 0 C--N 1.324 -0.509 0 CA-C-O 122.015 0.912 . . . . 0.0 109.453 179.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 57.4 m -128.35 144.46 51.13 Favored 'General case' 0 C--N 1.326 -0.431 0 CA-C-N 115.018 -0.992 . . . . 0.0 110.583 -179.774 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.451 ' HB2' ' HB3' ' A' ' 2' ' ' CYS . 36.2 m-20 -59.65 145.51 44.47 Favored 'General case' 0 C--N 1.326 -0.439 0 O-C-N 123.588 0.555 . . . . 0.0 109.842 179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -51.52 122.95 8.81 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.044 -0.526 . . . . 0.0 111.719 -179.003 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 116.8 -43.15 1.71 Allowed Glycine 0 N--CA 1.447 -0.571 0 CA-C-N 115.684 -0.689 . . . . 0.0 111.7 -179.495 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 83.6 m -90.72 114.47 26.81 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.033 0.444 . . . . 0.0 110.374 179.527 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.4 p90 -73.04 147.54 44.97 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-N 115.825 -0.625 . . . . 0.0 111.132 -179.833 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 42.8 t -72.8 117.72 14.84 Favored 'General case' 0 C--N 1.324 -0.511 0 N-CA-C 108.12 -1.067 . . . . 0.0 108.12 178.382 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 50.8 ttt-85 -113.23 124.15 32.04 Favored Pre-proline 0 C--N 1.322 -0.616 0 C-N-CA 120.564 -0.455 . . . . 0.0 111.962 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -67.54 160.66 46.96 Favored 'Trans proline' 0 N--CA 1.46 -0.46 0 C-N-CA 122.635 2.224 . . . . 0.0 109.975 177.621 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 36.6 t70 -56.03 -55.64 30.43 Favored 'General case' 0 C--N 1.323 -0.572 0 CA-C-O 120.969 0.414 . . . . 0.0 111.056 -179.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -157.11 -141.35 3.15 Favored Glycine 0 N--CA 1.441 -1.024 0 C-N-CA 120.511 -0.852 . . . . 0.0 112.558 179.323 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 17.3 m -84.29 132.32 31.85 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 CA-C-O 121.123 0.487 . . . . 0.0 111.662 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.69 30.42 76.27 Favored Glycine 0 N--CA 1.452 -0.259 0 CA-C-N 115.478 -0.783 . . . . 0.0 113.156 179.559 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 26.4 mt -128.09 135.01 63.92 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.446 0 N-CA-C 109.941 -0.392 . . . . 0.0 109.941 179.413 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.407 HG12 HD11 ' A' ' 9' ' ' LEU . 28.5 m -89.38 -31.47 5.39 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.73 0 CA-C-N 115.9 -0.591 . . . . 0.0 111.5 -179.179 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -81.48 148.05 29.41 Favored 'General case' 0 C--N 1.325 -0.478 0 CA-C-N 116.023 -0.535 . . . . 0.0 110.446 179.897 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -169.48 -151.48 7.33 Favored Glycine 0 N--CA 1.446 -0.699 0 C-N-CA 120.938 -0.649 . . . . 0.0 111.962 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 14.1 p -152.11 144.7 15.86 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.572 0 CA-C-O 120.688 0.28 . . . . 0.0 110.754 179.912 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.457 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 33.3 m -64.76 137.13 57.61 Favored 'General case' 0 C--N 1.326 -0.456 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.374 179.533 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 30.3 m . . . . . 0 C--O 1.25 1.1 0 CA-C-O 118.926 -0.559 . . . . 0.0 111.034 179.734 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.668 0 N-CA-C 111.548 -0.621 . . . . 0.0 111.548 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . 0.433 ' SG ' ' HB2' ' A' ' 15' ' ' ASP . 17.3 m -118.23 36.12 4.48 Favored 'General case' 0 C--N 1.323 -0.561 0 CA-C-O 121.744 0.783 . . . . 0.0 109.707 -179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.77 74.43 4.33 Favored 'General case' 0 C--N 1.323 -0.586 0 CA-C-N 115.163 -0.926 . . . . 0.0 111.296 -179.682 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -60.43 -41.03 98.42 Favored Glycine 0 C--N 1.321 -0.286 0 CA-C-N 115.552 -0.749 . . . . 0.0 112.346 -179.828 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 60.2 tttp -176.33 -46.62 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.87 0.367 . . . . 0.0 110.199 179.363 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -165.63 176.34 8.15 Favored 'General case' 0 C--N 1.327 -0.393 0 CA-C-N 115.739 -0.664 . . . . 0.0 109.73 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . . . . . . . . . 17.0 t -151.55 167.69 27.28 Favored 'General case' 0 C--N 1.322 -0.598 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 179.784 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -154.18 128.37 9.02 Favored 'General case' 0 C--N 1.322 -0.6 0 N-CA-C 108.998 -0.741 . . . . 0.0 108.998 -179.676 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . . . . . . . . . 4.0 mm? -71.64 49.8 0.17 Allowed 'General case' 0 N--CA 1.466 0.331 0 N-CA-C 112.51 0.559 . . . . 0.0 112.51 -178.722 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 48.7 mt -98.85 -30.48 12.37 Favored 'General case' 0 C--N 1.324 -0.542 0 CA-C-O 121.301 0.572 . . . . 0.0 109.728 178.702 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -178.77 -136.15 2.52 Favored Glycine 0 N--CA 1.445 -0.736 0 CA-C-N 115.442 -0.799 . . . . 0.0 111.351 -179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.781 ' H ' HD23 ' A' ' 12' ' ' LEU . 2.1 pt? -95.87 126.86 41.42 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 109.263 -0.643 . . . . 0.0 109.263 178.837 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 7.6 t -161.05 42.79 0.16 Allowed 'General case' 0 C--N 1.317 -0.827 0 CA-C-O 121.659 0.742 . . . . 0.0 110.254 -179.251 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 11.2 t -166.45 173.97 9.41 Favored 'General case' 0 C--N 1.325 -0.497 0 CA-C-N 115.504 -0.771 . . . . 0.0 109.515 179.65 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . 0.433 ' HB2' ' SG ' ' A' ' 2' ' ' CYS . 47.5 m-20 -69.3 149.62 48.27 Favored 'General case' 0 C--N 1.322 -0.612 0 CA-C-N 116.054 -0.521 . . . . 0.0 110.901 -179.887 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -73.06 67.43 0.88 Allowed 'General case' 0 C--N 1.327 -0.412 0 CA-C-N 115.889 -0.596 . . . . 0.0 111.537 -179.858 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . -175.92 -37.09 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.635 0 N-CA-C 111.256 -0.738 . . . . 0.0 111.256 -179.802 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 80.6 m -95.56 123.56 39.17 Favored 'General case' 0 N--CA 1.445 -0.711 0 CA-C-O 121.064 0.459 . . . . 0.0 109.776 179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 45.2 p90 -78.83 141.15 37.96 Favored 'General case' 0 C--N 1.317 -0.83 0 CA-C-N 115.892 -0.595 . . . . 0.0 110.587 -179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 37.5 t -72.92 111.38 7.99 Favored 'General case' 0 C--N 1.323 -0.551 0 N-CA-C 109.354 -0.61 . . . . 0.0 109.354 179.759 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . 0.521 ' HG2' ' HD2' ' A' ' 22' ' ' PRO . 10.8 ttp180 -94.6 130.74 32.53 Favored Pre-proline 0 C--N 1.323 -0.566 0 CA-C-O 120.697 0.284 . . . . 0.0 110.792 -179.215 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . 0.521 ' HD2' ' HG2' ' A' ' 21' ' ' ARG . 45.3 Cg_endo -73.04 159.57 47.54 Favored 'Trans proline' 0 N--CA 1.456 -0.697 0 C-N-CA 122.334 2.023 . . . . 0.0 110.797 178.49 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 48.0 t0 -60.11 -53.76 53.97 Favored 'General case' 0 C--N 1.32 -0.686 0 CA-C-O 120.998 0.428 . . . . 0.0 110.24 -179.482 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -158.81 -142.85 3.5 Favored Glycine 0 N--CA 1.442 -0.949 0 C-N-CA 120.671 -0.776 . . . . 0.0 112.019 179.023 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.6 m -81.33 130.84 35.17 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 CA-C-O 121.179 0.514 . . . . 0.0 111.516 -179.864 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.06 32.13 81.5 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.373 -0.83 . . . . 0.0 113.391 179.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 21.5 mt -128.51 132.9 67.56 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.415 0 N-CA-C 109.887 -0.412 . . . . 0.0 109.887 179.401 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . . . . . . . . . 18.0 m -89.39 -29.25 5.12 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.687 0 CA-C-N 115.863 -0.608 . . . . 0.0 111.346 -179.658 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -84.25 151.35 24.86 Favored 'General case' 0 C--N 1.323 -0.581 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.083 179.958 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -174.17 -137.15 2.37 Favored Glycine 0 N--CA 1.447 -0.574 0 C-N-CA 120.546 -0.835 . . . . 0.0 112.557 -179.772 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 12.5 p -151.02 142.57 16.53 Favored 'Isoleucine or valine' 0 C--N 1.324 -0.51 0 CA-C-O 120.766 0.317 . . . . 0.0 110.248 179.962 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . . . . . . . . . 4.4 t -75.16 136.65 41.04 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 109.477 -0.564 . . . . 0.0 109.477 -179.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 32.6 m . . . . . 0 C--O 1.247 0.931 0 CA-C-O 119.015 -0.517 . . . . 0.0 111.873 -178.896 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.481 1.682 0 N-CA-C 111.607 -0.597 . . . . 0.0 111.607 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' CYS . . . . . . . . . . . . . 31.0 m -119.71 34.51 5.19 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 120.941 0.4 . . . . 0.0 110.821 -179.266 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -79.94 53.06 1.6 Allowed 'General case' 0 C--N 1.324 -0.514 0 CA-C-O 121.304 0.573 . . . . 0.0 111.687 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . . . . . . . . . . . -68.26 -41.27 86.55 Favored Glycine 0 C--N 1.312 -0.757 0 N-CA-C 110.454 -1.058 . . . . 0.0 110.454 178.836 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . 0.417 ' HD3' ' HA ' ' A' ' 5' ' ' LYS . 69.3 mmtt -148.68 144.04 26.87 Favored 'General case' 0 C--N 1.327 -0.389 0 N-CA-C 109.056 -0.72 . . . . 0.0 109.056 178.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -56.99 124.48 18.81 Favored 'General case' 0 C--N 1.327 -0.401 0 CA-C-O 120.94 0.4 . . . . 0.0 110.513 179.856 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' CYS . . . . . 0.619 ' SG ' ' HA ' ' A' ' 13' ' ' THR . 44.8 t -89.61 116.07 27.48 Favored 'General case' 0 C--N 1.322 -0.622 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.439 -179.353 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . 0.426 HD21 HG23 ' A' ' 28' ' ' VAL . 0.7 OUTLIER -102.26 -3.16 27.72 Favored 'General case' 0 C--N 1.325 -0.484 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.345 -179.438 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' LEU . . . . . 0.405 ' HB2' ' O ' ' A' ' 8' ' ' ASN . 3.4 mm? 70.92 -44.45 0.59 Allowed 'General case' 0 N--CA 1.474 0.768 0 C-N-CA 123.347 0.659 . . . . 0.0 112.139 179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' LEU . . . . . . . . . . . . . 90.6 mt -50.12 -39.85 44.29 Favored 'General case' 0 N--CA 1.465 0.28 0 C-N-CA 123.27 0.628 . . . . 0.0 112.255 -179.34 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -157.87 42.86 0.51 Allowed Glycine 0 N--CA 1.45 -0.428 0 C-N-CA 120.567 -0.825 . . . . 0.0 111.908 179.97 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LEU . . . . . 0.615 HD12 ' HA ' ' A' ' 7' ' ' CYS . 2.5 tm? -174.52 137.29 0.48 Allowed 'General case' 0 C--N 1.327 -0.405 0 N-CA-C 108.857 -0.794 . . . . 0.0 108.857 -179.834 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . 0.619 ' HA ' ' SG ' ' A' ' 7' ' ' CYS . 10.8 t -163.47 145.19 9.53 Favored 'General case' 0 C--N 1.325 -0.484 0 N-CA-C 109.457 -0.572 . . . . 0.0 109.457 179.843 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' CYS . . . . . . . . . . . . . 61.9 m -96.38 167.46 11.16 Favored 'General case' 0 C--N 1.324 -0.53 0 CA-C-O 120.948 0.404 . . . . 0.0 111.704 -178.642 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ASP . . . . . . . . . . . . . 1.8 m-20 -57.09 155.32 8.54 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-N 115.427 -0.806 . . . . 0.0 111.519 -179.551 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ALA . . . . . . . . . . . . . . . -57.13 119.97 7.26 Favored 'General case' 0 C--N 1.331 -0.234 0 CA-C-N 115.707 -0.679 . . . . 0.0 111.436 -179.841 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' GLY . . . . . . . . . . . . . . . 138.38 -57.49 0.64 Allowed Glycine 0 N--CA 1.448 -0.53 0 N-CA-C 110.385 -1.086 . . . . 0.0 110.385 -179.418 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' CYS . . . . . . . . . . . . . 73.7 m -89.62 77.62 7.14 Favored 'General case' 0 C--N 1.322 -0.607 0 N-CA-C 109.078 -0.712 . . . . 0.0 109.078 178.004 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . . . . . . . . . 46.5 p90 -54.37 141.41 30.42 Favored 'General case' 0 C--N 1.324 -0.505 0 CA-C-N 115.579 -0.737 . . . . 0.0 111.917 -178.46 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' CYS . . . . . . . . . . . . . 97.9 m -72.44 88.77 1.22 Allowed 'General case' 0 C--N 1.323 -0.576 0 CA-C-N 115.351 -0.84 . . . . 0.0 109.639 179.171 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ARG . . . . . . . . . . . . . 26.3 ttt-85 -72.89 120.59 81.7 Favored Pre-proline 0 C--N 1.322 -0.609 0 CA-C-N 116.349 -0.387 . . . . 0.0 110.834 -179.149 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -69.94 157.38 60.25 Favored 'Trans proline' 0 N--CA 1.461 -0.435 0 C-N-CA 122.988 2.458 . . . . 0.0 110.823 178.741 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 9.3 t70 -52.87 -54.73 30.25 Favored 'General case' 0 C--N 1.326 -0.448 0 O-C-N 123.349 0.406 . . . . 0.0 110.608 -179.431 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' GLY . . . . . . . . . . . . . . . -156.69 -141.72 3.24 Favored Glycine 0 N--CA 1.441 -1.001 0 C-N-CA 120.819 -0.705 . . . . 0.0 111.958 179.017 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' VAL . . . . . . . . . . . . . 16.5 m -83.78 130.57 35.63 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.634 0 CA-C-O 121.106 0.479 . . . . 0.0 111.656 -179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 66.05 34.27 87.87 Favored Glycine 0 N--CA 1.453 -0.213 0 CA-C-N 115.441 -0.8 . . . . 0.0 113.352 179.554 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ILE . . . . . . . . . . . . . 33.0 mt -127.73 134.73 64.82 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.443 0 N-CA-C 109.885 -0.413 . . . . 0.0 109.885 179.441 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.426 HG23 HD21 ' A' ' 8' ' ' ASN . 20.5 m -89.44 -29.78 5.14 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.696 0 CA-C-N 115.683 -0.689 . . . . 0.0 111.347 -179.319 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ALA . . . . . . . . . . . . . . . -73.06 135.84 44.9 Favored 'General case' 0 C--N 1.325 -0.466 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.354 179.991 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLY . . . . . . . . . . . . . . . -166.74 -156.97 10.0 Favored Glycine 0 N--CA 1.445 -0.766 0 C-N-CA 120.358 -0.925 . . . . 0.0 112.299 179.994 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.577 ' HA ' ' H ' ' A' ' 7' ' ' CYS . 12.9 p -152.62 145.89 15.25 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.619 0 CA-C-O 120.604 0.24 . . . . 0.0 110.403 -179.985 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' CYS . . . . . 0.515 ' SG ' ' HB2' ' A' ' 7' ' ' CYS . 37.8 m -69.93 135.11 49.11 Favored 'General case' 0 C--N 1.324 -0.524 0 N-CA-C 109.746 -0.465 . . . . 0.0 109.746 179.542 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 35.7 m . . . . . 0 C--O 1.246 0.882 0 CA-C-O 118.75 -0.643 . . . . 0.0 111.318 -179.698 . . . . . . . . 0 0 . 1 stop_ save_